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MIV / VIGS is 'n ernstige gesondheidsbelasting, wat teen die einde van 2017 wêreldwyd 36,9 
miljoen mense affekteer. Suid-Afrika het die grootste MIV-1-epidemie ter wêreld, met 7,2 miljoen 
mense geafekteer teen die einde van 2017. Die MIV-1-epidemie in Suid-Afrika word oorheers deur 
MIV-1 subtipe C, wat verantwoordelik is vir 'n geskatte 98,2% van die infeksies in die land, 
gebaseer op die virusse in die Los Alamos Nasionale Biblioteek (LANL) databasis. Tot op datum is 
22 referate gepubliseer oor nie-subtype C virusse in Suid-Afrika tot die beste van ons wete. Hierdie 
studie het ten doel om twee naby vollengte-genoomvolgorde van nie-subtype C virusse in Suid-
Afrika te karakteriseer. 
Die studiemonsters is verkry deur die diagnostiese dienste van die Nasionale Gesondheids 
Laboratoriumdienste (NHLS), wat roetine dwelm weerstand toetsing in die Afdeling Mediese 
Virologie, Universiteit Stellenbosch, uitvoer. Alle monsters wat ontvang is, se genoom volgorde van 
die gedeeltlike pol streek (~ 1.4kb) was bepaal deur die NHLS. Die moontlike subtipe van die virus 
is geïdentifiseer deur die volgorde te analiseer met behulp van aanlyn subtipieërings programme. 
Alle vologordes en monsters wat as moontlike nie-subtype C virusse geïdentifiseer is, is in 'n 
aparte C-kohort van nie-subtype aangeteken. In 2011 is 'n moontlike C, D rekombinante virus vir 
die eerste keer geïdentifiseer in hierdie kohort. Teen die einde van 2015 is 30 soort gelyke 
rekombinante virusse waargeneem in die kohort, wat 'n moontlike opkoms van hierdie 
rekombinante stam aandui. Twee van die monsters wat as moontlike C, D-rekombinante 
geïdentifiseer is, is gekies vir naby-vol lengte-genoom (NFLG) karakterisering. 
Provirale DNA, van monster EC148, is onttrek uit PBMCs en virale RNA. Plasma is onttrek van uit 
monster WC416. Die RNA was getru getransskribeer na DNA via cDNA sintese. Beide  virus 
monsters het  twee rondes PKR ondergaan. Die eerste ronde het die versterking van die MIV-1 
NFLG (8978bp) geteiken en die tweede het die versterking van twee oorvleuelende fragmente 
(5455bp en 4909bp) geteiken. Positiewe PKR amplikone is gesuiwer en volgorde bepaal. Die 
gegenereerde volgordes is gelees en ontleed voordat dit gebruik was,deur gebruik te maak van 
aanlyn subtipeërings programme. Die jumping profile hidden markov model (jpHMM), REGA en 
rekombinasie-identifikasieprogramme (RIP) is gebruik om voorlopige subtipes vir beide monsters 
te bepaal. Verder is filogenetiese ontledings gebruik om die aanlyn subtipeërings program se 
resultate te bevestig of te verwerp. 
Die aanlyn subtipeërings programme het monsters EC148 en WC416 as komplekse A, C, D 
rekombinante geïdentifiseer. Filogenetiese analise het die aanlyn subtipeërings program se 
resultate vir die volgorde van monster WC416 bevestig as  komplekse A, C, D rekombinante. 
Filogenetiese analise het aangedui dat die volgorde van monster EC148 in ooreenstemming is met 
die resultate wat vanaf die aanlyn subtipeërings programme waargeneem word. Elke MIV-1-
volgorde wat geïdentifiseer is as 'n unieke komplekse rekombinante vorm omskryf, omrede die 
breekpunte tussen die verskillende subtipes verskil het. 
Stellenbosch University  https://scholar.sun.ac.za
 
iv 
Die opkoms van nuwe en unieke nie-subtipe C rekombinante in Suid-Afrika dui aan dat die 
epidemie kompleks en ontwikkelend is. Dit is dus belangrik om die verspreiding van verskillende 
MIV-subtipes wat in Suid-Afrika versprei word, te monitor. 
 
  




HIV/AIDS is a severe health burden, affecting 36.9 million people worldwide by the end of 2017. 
South Africa has the largest HIV-1 epidemic in the world, estimated at 7.2 million infected 
individuals by the end of 2017. The HIV-1 epidemic in South Africa is dominated by HIV-1 subtype 
C, accounting for an estimated 98.2% of the infections in the country, based on the viral sequences 
in the Los Alamos National Library (LANL) database. To date, to the best of our knowledge, 22 
papers have been published on non-subtype C viruses in South Africa. This study aimed to 
characterise two near full-length genome sequences of non-subtype C viruses in South Africa.  
The study samples were obtained through the diagnostic services of the National Health 
Laboratory Services (NHLS), performing routine drug resistance testing within the Division of 
Medical Virology, Stellenbosch University. All samples received were sequenced in the partial pol 
region (~1.4kb) of the viral genome by the NHLS. The possible subtype of the virus was identified 
from the sequences using online subtyping programmes. All sequences and samples that identified 
as possible non-subtype C viruses were recorded in a separate non-subtype C cohort. In 2011, a 
possible C, D recombinant virus was first identified in this cohort. By the end of 2015, 30 similar 
recombinant viruses were observed in the cohort, indicating a possible emergence of this 
recombinant strain. Two of the samples that identified as possible C, D recombinants were 
selected for further near full-length genome (NFLG) characterisation.  
Proviral DNA, from sample EC148, was extracted from PBMCs and viral RNA, from sample 
WC416, was extracted from plasma. The RNA was reverse transcribed to DNA via cDNA 
synthesis. Both sample viruses were amplified by PCR in two rounds. The first round targeted the 
amplification of the HIV-1 NFLG (8978bp) and the second targeted the amplification of two 
overlapping fragments (5455bp and 4909bp). Positive PCR amplicons were purified and 
sequenced. The generated sequences were read and analysed before being used in online 
subtyping programmes. The jumping profile hidden markov model (jpHMM), REGA and 
recombination identification programmes (RIP) were used to preliminary assign subtypes to both 
samples. Phylogenetic analyses was inferred to confirm / reject the online subtyping programme 
results. 
Online subtyping programmes identified the virus sequences of samples EC148 and WC416 as 
complex A, C, D recombinants. Phylogenetic analysis confirmed the online subtyping programme 
results for the sequence of sample WC416 in identifying it as a complex A, C, D recombinant. 
Phylogenetic analysis indicated that the sequence of sample EC148 is consistent with the results 
observed from the online subtyping programmes. Each HIV-1 sequence identified as a unique 
complex recombinant form as the breakpoints between the different subtypes differed. 
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The emergence of new and unique non-subtype C recombinants in South Africa indicates that the 
epidemic is complex and evolving. It is therefore important to monitor the spread of different HIV 
subtypes circulating in South Africa.   
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1.1. Introduction  
Human immunodeficiency virus (HIV) is the causative agent of acquired immune deficiency 
syndrome (AIDS) (Barré-Sinoussi et al., 1983). HIV has infected over 76 million individuals since 
the start of the epidemic. It has become a major health burden since its discovery, affecting 36.7 
million people globally by the end of 2017. In 2016 alone, 1 million individuals died from AIDS 
related illnesses. Eastern and Southern Africa are the most affected geographical region in the 
world, having 19.6 million individuals living with HIV and was responsible for 380 000 AIDS-related 
deaths by the end of 2017. South Africa is the country with the largest population of HIV-infected 
individuals in the world, which was 7.2 million by the end of 2017. In that same year there 
were110 000 AIDS-related deaths in South Africa.  
HIV is a retrovirus with a diploid RNA genome. A unique feature of retroviruses is that they 
possess reverse transcriptase (RT) that allows the virus to enter a host cell, reverse transcribe the 
RNA genome to DNA and then integrate it into the host cell genome. Upon entry of a HIV particle 
into a host cell, the virus is able to use the host cells’ machinery to replicate and produce progeny 
viruses (Krieg and Steinberg, 1990). 
It is believed that HIV was transmitted to humans via a zoonotic transmission event from infected 
African primates and has spread rapidly through the human population since then (Essex and 
Kanki, 1988). Phylogenetic analyses have revealed that HIV exists in two forms, HIV type 1 (HIV-1) 
and HIV type 2 (HIV-2). HIV-1 has spread across the world; however, HIV-2 is endemic to West 
Africa. HIV-1 is divided into groups M (major), N (Non-M), O (Non-N) and P with group M being 
responsible for the pandemic. Group M is further divided into subtypes and recombinant forms. 
Recombinant forms can either be a unique recombinant form (URF) or a circulating recombinant 
form (CRF). A CRF is found in three individuals who are not epidemiologically related whereas a 
URF is found in only individual and has the potential to become a CRF. (Hahn et al., 2000).  
HIV-1 (group M) subtypes A, B and C are responsible for the majority of infections worldwide. The 
different subtypes are not evenly distributed and are predominant in different regions. Subtype B is 
predominant in Europe and the United States of America (USA), subtype A is predominant in Asia 
and subtype C is largely predominant in sub-Saharan Africa (van Harmelen et al., 1999). Looking 
at South Africa in particular, the epidemic is almost completely dominated by subtype C viruses 
(Hemelaar, 2012). However, the emergence of non-subtype C viruses have been increasing over 
recent years. Recombinant viruses are becoming more prevalent across the world. This is seen in 
South East Asia where the epidemic is led by the recombinant CRF01_AE (Lau et al., 2013). By 
October 2018, 97 recombinant forms have been identified and documented in the HIV Los Alamos 
National Library (LANL) database 
(https://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html; Accessed 31/10/18).  
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Recombinant viruses have been shown to have an impact on viral diagnostics, vaccine 
development, antiretroviral drug resistance as well as disease progression. Therefore, it is vital that 
the emergence of these viruses are monitored (Hemelaar, 2013).  
1.2. Aims 
The aim of the project is to characterize two possible new HIV-1 C, D recombinant viruses in South 
Africa through recombinant and phylogenetic analyses. 
1.3. Objectives 
1. DNA/RNA extraction, PCR and conventional Sanger sequencing of HIV-1 NFLG 
2. HIV-1 recombinant analyses 
3. Phylogenetic analyses 
1.4. Rationale 
South Africa has the highest incidence of HIV-infected individuals in the world. The epidemic is 
dominated by HIV-1 subtype C; however, there is an increasing emergence of non-subtype C 
viruses in the country. This study focuses on non-subtype C viruses in South Africa, particularly C, 
D recombinants. HIV-1 subtype C has been extensively studied in the South African context with 
only a limited number of studies being conducted on non-subtype C viruses. Studying the non-
subtype C viruses in the country will increase our knowledge and understanding of the entire 
epidemic in South Africa. It is important that subtype diversity be monitored as studies have shown 
different subtypes to have faster progression to AIDS and to be more resistant to antiretroviral 
treatment than other subtypes. Recombinant viruses, being composed of 2 or more different 
viruses, has the potential to be more resistant to ARV treatment than pure subtypes. Constant 
monitoring of all circulating viruses will give a more accurate representation of the evolution of HIV-
1 in South Africa. In 2011, four possible C, D recombinants were noticed in a non-subtype C cohort 
obtained from the NHLS. By the end of 2015, this number increased to 30. The sudden emergence 
and increase of this particular recombinant required that it be fully characterised. 
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The first official report of acquired immunodeficiency syndrome (AIDS) was issued by the United 
States of America’s (USA) Centers for Disease Control and Prevention (CDC) in 1981. A Morbidity 
and Mortality Weekly Report (MMWR) was released stating that previously healthy homosexual 
men presented with a lung infection known as Pneumocystis carinii pneumonia (PCP) and some 
presented with a rare cancer called Kaposi’s Sarcoma (KS) (CDC, 1981). A year later the CDC first 
used the term AIDS. The CDC defined a case of AIDS as: “a disease at least moderately predictive 
of a defect in cell mediated immunity, occurring in a person with no known cause for diminished 
resistance for that disease” (CDC, 1982).  
Soon after the identification of AIDS and its associated characteristics (CDC, 1982), Dr. Robert 
Gallo and his team identified a virus that shared characteristics with the causative agent of AIDS in 
that it was transferred between individuals via mother-to-child transmission, sexual contact and 
through blood. The virus also resulted in lower CD4+ T-cells in infected individuals (Barré-Sinoussi 
et al., 1983; Gallo et al., 1984). The identified virus was named human T-cell leukaemia associated 
virus-3 (HTVL-III) (Gallo et al., 1984). At the same time, a research group at the Pasteur Institute in 
France, who focused on retrovirus research set out to discover if a retrovirus was the causative 
agent for AIDS. Their research led to the discovery of the lymphadenopathy associated virus 
(LAV), which also displayed characteristics similar to those seen in AIDS patients (Ellrodt et al., 
1984; Barré-Sinoussi et al., 1983). Upon further investigation of HTVL-III and LAV, it was 
discovered that they were the same virus and that it was the causative agent for AIDS. The virus 
was later named human immunodeficiency virus (HIV) (Coffin et al., 1986). 
2.1.2. Origin 
In 1984 the primate Lentivirus, Simian Immunodeficiency Virus (SIV), was isolated from primates 
displaying an AIDS-like disease (Marx et al., 1985; Chakrabarti et al., 1987). Characterization of 
SIV revealed that this virus was very similar to HIV in that they both target the same CD4 subset of 
lymphocytes. SIV and HIV were also shown to have the same internal core proteins and their 
structural and regulatory genes were organized in an almost identical manner (Essex and Kanki, 
1988).  
In 1985, a virus related to SIV was found in blood samples of prostitutes from Senegal (Clavel et 
al., 1986). The blood samples contained antigens for both HIV and SIV. The antigens present in 
the blood samples had higher reactivity with SIV than it did to HIV. The reactivity of the antigens to 
SIV in these blood samples resembled the antigen to SIV reactivity seen in SIV-infected Asian 
macaques. 
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Figure 2.1: Transmission of SIV to humans (Gallo et al., 1999) 
The transmission of SIVsmm from Sooty mangabeys gave rise to HIV-2 in humans. HIV-1 originated from 
a cross species transmission event of SIVcpz from the chimpanzee subspecies, Pan troglodytes 
troglodytes. SIV is able to cross the species barrier and transmit to both humans and non-human 
primates. 
 
This suggested that this virus was different to the HIV infecting people in the USA and Europe. 
Upon further characterisation of the virus, it was identified as a close relative to HIV-1 and was 
named HIV-2 (Essex and Kanki, 1988; Etienne et al., 2011). The transmission of SIV from Sooty 
mangabeys (SIVsm) to humans in West Africa was discovered, through phylogenetic analysis, as 
the origin of HIV-2 (Gao et al., 1999; Etienne et al., 2011).  
Most primates harbour a species-specific strain of SIV (example: Sooty mangabeys harbour 
SIVsm) suggesting that transmission of that specific SIV strain is transferred between members of 
the same species (Etienne et al., 2011). HIV-1 viral sequences were most closely related to Pan 
troglodytes.troglodytes, a sub-species of the P.troglodytes lineage and was discovered to be the 
origin of HIV-1 infections in humans (Gao et al., 1999; Sharp and Hahn, 2011). HIV is therefore 
most likely a result of a transmission event between humans and African primates. The cross-
species transmission between the primates and humans was presumably due to direct exposure to 
the blood of the primates, which could have been as a result of eating the meat raw, hunting or 
butchering of the animals (Buonaguro et al., 2007). Molecular clock analyses dates the origin of 
HIV-1 group M to 1931 (Korber et al., 2000). Figure 2.1 shows the origin of HIV transmission 
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2.2. Basic virology of HIV 
2.2.1. Classification 
Retroviruses can be classified as either having simple genomes (the alpha, beta, gamma and 
epsilson retroviruses) or complex genomes (the lentiviruses, deltaviruses and spumaviruses) 
(Weiss, 2006). All retroviruses are composed of the group antigen (gag), polymerase (pol) and 
envelope (env) genes as well as long terminal repeats (LTR), which contain promoter and 
















In 1910, Peyton Rous from the Rockefeller Institute for Medicine in New York, identified a sarcoma 
of the common fowl, which proved to be transplantable to other fowls. The virus responsible for the 
sarcoma was named the Rous Sarcoma Virus and was the first documented discovery of a 
retrovirus (Rous, 1910). Since then retroviruses have been identified in tumours of many animals 
including mice, chicken and cats (Huebner and Todaro, 1969).  
The central dogma of molecular biology states that the natural flow of genetic material is from DNA 
to RNA to protein (Gallo, 2005). However, in retroviruses, the genetic material is transferred from 
RNA to DNA to RNA and then to protein. The RNA of an infecting virus is first converted to proviral 
DNA that integrates into the host cell’s genome and is then used as a template for the generation 
of progeny RNA, which is homologous in sequence to the RNA of the infecting virus (Gallo, 1986). 
Figure 2.2: Phylogeny of retroviruses (Weiss, 2006) 
The phylogenetic tree illustrates the various classifications of retroviruses. HIV-1 and 
HIV-2 are both classified as a lentivirus, which is a complex retrovirus.  
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Figure 2.3: Virion structure (https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/19/73/the-hiv-life-cycle; 
Accessed 22/10/18) 
The basic structure of a retrovirus consists of two RNA molecules and enzymes such as reverse transcriptase, 
enclosed in a viral capsid. The capsid is surrounded by a lipid envelope membrane, which anchors proteins 
(glycoproteins) that protrude from its surface and facilitate attachment of the virus to host cells. 
If the proviral DNA integrates into a host germ cell, the virus will be passed down onto the host’s 
progeny as an endogenous retrovirus (Hayward, 2017). Howard Temin from the University of 
Wisconsin and David Baltimore at Massachusetts Institute of Technology, both independently 
discovered reverse transcriptase, the enzyme unique to retroviruses that is responsible for the 
conversion of RNA to proviral DNA (Baltimore, 1970; Temin, 1976). The discovery of reverse 
transcriptase allowed scientists to fully understand how retroviruses cause disease. The proviral 
state of the retrovirus allows for it to remain dormant within the host’s cells genome and to 
reactivate and replicate at a later stage (Weiss, 2006). The first isolated human retrovirus was 
HTLV-1 and was isolated in 1979 from a patient with a T-cell malignancy (Poiesz et al., 1980; 
Gallo, 2005). 
2.2.2. Virion and genome structure 
The HIV genome is encapsulated by a lipid bilayer derived from the host cell’s membrane, known 
as the viral envelope. Surface glycoproteins are anchored in the envelope and protrude outwards 
to facilitate the attachment of the virion to a host cells’ receptor molecules (Briggs et al., 2003). 
Within the viral envelope is a core that is composed of a number of proteins and a capsid that 
contains two molecules of RNA. It is within the core that the necessary genetic information for viral 
replication is stored. The reverse transcriptase is bound to the RNA molecules and is responsible 
for the transcription of a DNA molecule by using the RNA as a template (Turner and Summers, 
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1999). Figure 2.3 illustrates the components and structure of the HIV virion. 
 
The HIV genome is complex and comprises of structural, regulatory and accessory genes. The 
following genes make up the HIV genome: the gag, pol, env, transactivator (tat), regulatory factor 
(rev), viral infectivity factor (vif), viral protein R (vpr), viral protein U (vpu) and the negative 
regulatory factor (nef). The gag, pol and env are structural genes; tat and rev are regulatory genes 
while vif, vpr,vpu and nef are accessory genes (Costin, 2007).  
The structural proteins are essential components of the viral particle. Figure 2.4 shows the 
arrangement of genes within the genome. The gag gene encodes the capsid proteins that houses 
the RNA molecules; the pol gene produces protease, reverse transcriptase, RNase and integrase; 
the env gene encodes the envelope glycoproteins gp120 and gp41. The tat and rev regulatory 
genes code for RNA binding proteins that are responsible for HIV gene expression. The accessory 
genes code for proteins, which have multiple functions. Vif is the viral infectivity factor that 
promotes the infectivity of the virus whereas vpu functions to reduce CD4 expression. The nef 
protein is mostly cytoplasmic and is associated with the plasma membrane (Costin, 
2007;  http://www.hiv.lanl.gov/; accessed: 30 August 2018). 
 
2.2.3. HIV Life cycle 
The HIV life cycle (Figure 2.5) is divided into in eight steps: attachment, fusion, reverse 
transcription, integration, replication, assembly, budding and maturation. The cycle is separated 
into an early and late phase. The early phase begins with the attachment of the virus to a host cell 
and includes all processes up to the integration of DNA into the host genome. The late phase 
includes all stages after integration until maturation.  
Figure 2.4: HIV-1 gene map (www.hivlanl.gov/ [Accessed on 10 May 2018]) 
The figure illustrates the positions of the different genes that make up the HIV genome. The numbers at the 
top denote the start position of the genes and the numbers at the bottom indicate their end positions. The 
genome begins at the 5’LTR and ends at the 3’LTR. 
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A free virus attaches to a host cell by binding of the viral envelope glycoprotein to the host cell 
receptor. HIV infects vital cells of the immune system such as helper T-cells. HIV-1 requires the 
presence of a co-receptor, known as chemokine co-receptors, to promote fusion of the virus into 
the host cell. HIV most commonly binds specifically to the CD4+ cell receptor and the CCR5 or 
CXCR4 chemokine co-receptor on the T-cell to promote fusion (Lawn, 2004). Fusion involves the 
transfer of the viral capsid through the host cell membrane and into its cytoplasm. Once in the 
cytoplasm, a process of uncoating takes place in which the contents of the capsid is released. 
Reverse transcriptase converts viral RNA to complimentary DNA (cDNA) via reverse transcription. 
The DNA and the integrase enzyme move from the cytoplasm into the nucleus where the enzyme’s 
activity enables the integration of the DNA into the host cells’ genome, as a provirus. At this stage, 
the early phase is complete (Turner and Summers, 1999). A unique feature of retroviruses is the 
ability of the provirus to remain dormant in the host cell genome, allowing it to evade antiretroviral 
therapy (ART), which could stop the virus from replicating (Finzi et al., 1997). 




Figure 2.5: HIV life cycle, NIH, 2018 (accessed 22 June 2018)  
The figure illustrates the different stages of the HIV life cycle. A free virus attaches itself to a host cell and 
ejects its contents into the host cell. Viral RNA is converted to DNA which is then integrated into the host 
cell’s DNA. The integrated DNA is used to make copies of the viral RNA and proteins. The newly synthesised 
components are assembled and released from the cell. Once the new virus has matured, it is able to infect 
neighbouring host cells. 
 
The late phase begins with the replication step in which the proviral DNA uses the host cells’ 
machinery to transcribe messenger RNA (mRNA). The mRNA is exported from the nucleus to the 
cytoplasm where it is translated into regulatory and structural proteins. The RNA and proteins are 
assembled and packaged into a new immature virus particle at the surface of the cell. The virus 
exits the host cell by pushing itself through the cell membrane in a process called budding. This 
process allows the virus to use the host’s cell membrane as its viral envelope membrane. Upon 
release, viral protease cleaves the proteins to create a mature infectious virus. The new mature 
virus is able to infect neighbouring cells and continue the cycle. The HIV life cycle is complex and 
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involves a number of intricate processes to ensure the success of the virus in the host organism 
(Sundquist and Krusslich, 2012). 
2.3. HIV diversity 
2.3.1. HIV-1 and HIV-2 
A key characteristic of HIV-1 is the extreme genetic diversity of its viral genome, which is 
associated with the persistent nature of the virus, drug resistance to ART, as well as the difficulty in 
designing a successful vaccine (Smyth et al., 2012). The two major mechanisms responsible for 
HIV diversity is mutation and retroviral recombination. The mutations most often arise as a result of 
an error by the RNA polymerase, reverse transcriptase, as it lacks proof reading activity and 
therefore has a high error rate (Lau et al., 2013). Retroviral recombination occurs when regions of 
different viruses recombine to form a new virus. These regions usually contain properties that are 
beneficial to the virus. This process allows the virus to acquire advantageous mutations and 
remove mutations that could reduce viral fitness (Korber et al., 2001; Smyth et al, 2012).  
HIV is divided into two forms, HIV-1 and HIV-2, which can be identified based on the organisation 
of their genome and their phylogenetic relationship with other primate lentiviruses (Hahn et al., 
2000). The two types of HIV can be divided into HIV-1 groups M (major), N (Non-M), O (Non-N) 
and P and HIV-2 groups A-H, with each group most likely originating as a result of an independent 
zoonotic transmission from African primates to humans (Duri et al, 2013). HIV-1 group M and N 
originate from SIVcpz found in the chimpanzee subspecies, Pan troglodytes troglodytes, endemic 
to West-central Africa. Whereas HIV-1 groups O and P originate from SIVgor found naturally in 
gorillas located in Cameroon (Hemelaar, 2012). HIV-1 group M is responsible for the HIV 
pandemic and can be further divided into subtypes, sub-subtypes and recombinant forms. Nine 
subtypes have been identified and are denoted by the letters A-D, F-H, J and K (Hemelaar, 2013). 
The intra-subtype genetic variation ranges between 15-20% and the inter-subtype genetic variation 
ranges between 25-35% (Korber et al., 2001). The co-circulation of the different subtypes have 
resulted in the emergence of recombinant forms. A recombinants form is a virus composed of 
segments from two or more different subtypes. Recombinants are classified as either a circulating 
recombinant form (CRF) or a unique recombinant form (URF). A URF is classified as a 
recombinant that has been identified in less than three epidemiologically unrelated individuals 
(Perrin et al, 2003).The spread of a URF gives rise to a new CRF (Hemelaar, 2013). A 
recombinant virus is classified as a CRF if it is fully sequenced and identified in at least three 
epidemiologically unrelated individuals. Currently there are 97 CRFs globally 
(https://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html; [Accessed October 2018]). 
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2.3.2. Global diversity 
HIV-1 group M is responsible for the HIV/AIDS pandemic. The different subtypes from this group 
are spread across the world, with subtypes A, B and C being most prevalent as seen in Figure 2.6 
(Hemelaar et al., 2011; Hemelaar, 2012). Subtype C accounts for almost 50% of the global 
infections, making it the dominant subtype of the pandemic.  
 
The unequal global distribution of HIV-1 group M variants is a result of epidemiologic 
transmissions; the dynamic nature of the HIV pandemic and global variation in the HIV-strains (Lau 
et al., 2013). Figure 2.7 shows the distribution of the subtypes across the world between 2004-
2007. This is the latest representation of HIV-1 global diversity found in the literature. Subtype A is  
Figure 2.6: Global distribution of HIV- 1 pure subtypes and recombinants (Hemelaar et al., 2012) 
There is a slight variation in the results observed in the two time points. In 2004-2007, subtype C was the 
most prevalent global subtype followed by subtype B and A. CRF02_AG is the most prevalent of the CRFs 
followed by CRF01_AE. 
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dominant in East and Central Africa as well as in Eastern Europe. Subtype B is the main variant in 
Western and central Europe, North and South America, Australia, countries in central Asia, 
northern Africa and the Middle East. Subtype C is responsible for a large majority of the epidemics 
in South Africa, Ethiopia and India. The epidemics in these regions are almost exclusively subtype  
 
C, with only a small proportion of non-subtype C infections. All subtypes are present in West Africa, 
with subtype G and CRF02_AG being dominant. In South and East Asia, the epidemic is 
dominated by CRF01_AE. Subtype D is mostly found in East Africa. The subtype B epidemic is 
widely and evenly spread across the world. The greatest diversity is observed in central Africa 
where all subtypes and numerous CRFs are present (Hemelaar et al., 2011).  
2.3.3. HIV-1 diversity in South Africa 
The initial HIV-1 epidemic in South Africa, in the early 1980s, was led by subtype B and D viruses 
and was associated with homo- and bisexual transmission (Engelbrecht et al., 1995; Becker et al., 
1995). Soon after (late 80’s, early 1990s), a subtype C epidemic was recognized among 
heterosexual individuals. Heterosexual and mother-to-child transmission are the main routes of 
HIV transmission in South Africa (van Harmelen et al., 2001; Jacobs et al., 2009; Wilkinson and 
Engelbrecht, 2009). It is believed that the HIV-1 subtype C virus originates from HIV-1 group M in 
central Africa. The ancestral subtype C is believed to have migrated from Kinshasa in the 
Figure 2.7: Regional distribution of HIV-1 subtypes and recombinants in 2004-2007 (Hemelaar et al., 2012) 
The map shows subtype B being dominant in the Americas, Europe and Northern Africa; Subtype A 
dominant in eastern Europe and East Africa whereas subtype C is dominant in South Africa, India and 
China. 
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Democratic Republic of Congo (DRC). Phylodynamics suggests that this migration occurred 
around the 1930s and that this virus then spread to East and Southern Africa. The HIV-1 subtype 
C virus is believed to have been introduced in South Africa in 1960 via immigrant mine workers 
from neighbouring African workers (Wilkinson et al., 2015a).  
Of the 36.7 million individuals infected with HIV globally, South Africa had 7.2 million people living 
with infections by the end of 2017, making it the country with the highest number of HIV infected 
individuals in the world (UNAIDS, 2018). According to the Los Alamos National Library database, 
98% of the infections are subtype C and the remaining 2.2% are non-subtype C viruses. The non-
subtype C viruses include subtypes A, B, D and G as well as AC, AG, CD, BC and complex 
recombinants (https://www.hiv.lanl.gov/; accessed 30 August 2018).  
2.3.4. Recombinant strains of HIV-1 
CRF01_AE is the first documented and reported HIV-1 recombinant. This CRF was first identified 
in Thailand in 1992, although, it was discovered to be of African origin (Carr et al., 1996; Gao et al., 
1996). Recombination is not limited to inter-subtype events, but is also observed between 
sequences of different HIV-1 groups. This was seen in a study in which a HIV-1 group M/group O 
recombinant was identified in a Cameroon women’s blood sample (Peeters et al., 1999). The 
discovery of this rare recombinant illustrates the possibility of new HIV-1 variants emerging.  
The prevelance of inter-subtype recombinants in the global pandemic is estimated at between 18-
20% (Buonaguro et al., 2007; Hemelaar et al., 2011). The formation of a viral recombinant requires 
co-infection or super-infection of two or more viruses into the same target cell (Liu et al., 2002). Co-
infection occurs when an individual is infected with two different strains at the same time, whereas 
super-infection occurs as a result of an already HIV-1 infected individual being infected with a new 
strain (Yerly et al., 2004).  
HIV is a diploid virus, containing two strands of RNA. Homologous recombination can occur in a 
cell that is co-infected with two different, but related strains (Burke, 1997). Retroviral recombination 
occurs often during reverse transcription and is a consequence of the virus having two viral 
genomes packaged into one virion (Hu and Temin, 1990; Moutouh et al., 1996). The viral RNA of 
both viruses (For example, a subtype A and subtype B virus) enter the host cell and is transcribed 
to DNA by the reverse transcriptase enzyme. The converted DNA of the subtype A virus and 
subtype B virus are integrated into the host cell’s genome. The proviral DNA strands are converted 
to RNA by the host cell’s RNA polymerase and is transported out of the cell’s nucleus and into the 
cytoplasm where they are packaged into the same virion. Once released from the cell, the new 
virion goes on to infect a neighbouring host cell in which its subtype A and B RNA strands are 
reverse transcribed (Taylor et al., 2008). The reverse transcriptase jumps back and forth between 
the two RNA strands, generating a recombinant of the two parent strands (Burke, 1997). The newly 
synthesised subtype A/B viral strands are integrated into the host cell’s genome. Upon replication, 
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mosaic subtype A and subtype B RNA strands are packaged into a new virion, creating an A, B 
recombinant virus (Figure 2.8). Each RNA strands of the recombinant virus will be composed of 
both parental subtypes (Taylor et al., 2008). 
 
Figure 2.8: Process of the formation of a recombinant HIV virus (Taylor, 2008) 
The process shows one target cell being infected with to different HIV subtypes. The viruses are reverse 
transcribed, integrated in to the host genome, then replicated and packaged into new virion. The new virion 
infects neighbouring cells and generate recombinant viruses. 
 
Recombinant viruses are most prevalent in regions where many subtypes co-circulate (Lau and 
Wong, 2013). A recombinant virus is characterised by having distinct regions of their genome 
match the consensus sequences for different pure subtypes. A region defined as a break point 
distinguishes between the two different subtype sequences within a recombinant genome. CRFs 
are named according to the subtypes present in their genome as well as a corresponding number 
indicating when the virus was identified (Ramirez et al., 2008). For example, CRF01_AE is the first 
reported and documented CRF and is composed of subtype A and subtype E genomic regions 
(Lau et al., 2013). Complex recombinants (denoted as CRF_cpx) have genomes that are 
composed of three or more different subtypes (Ramirez et al., 2008). The emergence of new CRFs 
are increasing considerably over the years. In 2013 there were 55 documented CRFs in the HIV 
Los Alamos database (Lau et al., 2013) and by October 2018 there were 97 (www.hiv.lanl.gov ; 
Accessed 30 October 2018). In a period of five years, 35 new CRFs have been documented.  
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2.4. Phylogenetic analyses methods 
2.4.1. Phylogenetics 
Phylogenetics is the study of finding relationships between species or genes using molecular 
biology and mathematics (Nee, May and Harvey, 1994; Lemey, Salemi and Vandamme, 2009). 
Molecular phylogenetics uses the information in DNA or genetic sequences to construct a 
phylogenetic/evolutionary tree based on the similarities and/or differences between the sequences. 
The more similar two sequences are, the closer they will be positioned on the tree (Wright, 2017). 
Phylogenetics is an integral component in HIV studies as it is able to determine the relatedness or 
divergence between different HIV groups/subtypes. Phylogenetic analyses are a key aspect of this 
project and a brief outline of each major step is described below. 
2.4.2. Aligning homologous sequences 
A multiple sequence alignment (MSA) is the foundation of any molecular phylogenetic analysis. A 
MSA is an alignment of sequences in which all nucleotides or amino acids in the same column of 
the alignment are considered to have a common evolutionary origin (Katoh, 2017). If the same 
nucleotide is observed at the same position in multiple sequences, the position is believed to be 
conserved in evolution. However, if the nucleotide in the same position differs between multiple 
sequences, it is believed that both derived from the same ancestral state, which could be one of 
the sequences in the multiple alignment or an entirely different sequence. The evolutionary theory 
states that all organisms have evolved from a common ancestor (Bacon and Anderson, 1986). A 
number of MSA programmes are available, including ClustalX, Multiple Alignment using Fast 
Fourier Transform (MAFFT), SAM T-coffee and Muscle. The programmes differ in several ways, 
mainly in their ability to align large numbers of sequences or complex sequences, and taxa that are 
only distantly related (Katoh et al., 2017; Wright, 2017). 
2.4.3. Selecting a model of evolution 
The evolutionary distance between two sequences is estimated based on the number of nucleotide 
substitutions between them. Nucleotide substitutions are categorised as either transitions or 
transversions. A transition is the substitution of a purine for a purine (adenosine or guanine) or a 
pyrimidine for a pyrimidine (thymine or cytosine). All other forms of substitutions are transversions 
(purine for pyrmidine or vice versa) (Nei and Kumar, 2000). Various mathematical models are used 
to estimate the evolutionary distance between sequences based on nucleotide substitutions. The 
most widely used methods are included in the MEGA model test tool. These include the Jukes-
Cantor, Tajima-Nei, Kimura 2-Parameter, Tamura 3-Parameter and Tamura-Nei models (Tamura 
et al., 2013). The three models most commonly used on HIV datasets are the Hasegawa, Kishino, 
Yano (HKY) (Hasegawa et al., 1985); the General Time-Reversible (GTR) (Yang et al., 1994) and 
Kimura 2-parameter (Kimura, 1980) models. These models are best at estimating the evolutionary 
Stellenbosch University  https://scholar.sun.ac.za
 
18 
distance between ancestral and query HIV sequences. A model test is therefore carried out on a 
dataset to determine which model best estimates the real evolutionary distance, as opposed to the 
observed distance, between the sequences.  
2.4.4. Phylogenetic tree inference 
A phylogenetic tree is a graphical representation of the evolutionary relationships between species 
based on their genetic closeness (Wright, 2017). A phylogenetic tree is useful in providing 
information about the origin and spread of disease and to discover evolutionary relationships 
between groups of organisms (Mahapatro et al., 2012). A phylogenetic tree consists of nodes 
connected by branches (Figure 2.10) (Hall, 2011). An internal node represents the last common 
ancestor of the branches diverting from it. External nodes represent the sequences used to derive 
the tree. The length of the branches correspond to the amount of evolution between the 
sequences. For example, a longer branch length indicates higher divergence (Baldauf, 2003).  
Figure 2.9: Nucleotide substitutions (Nei and Kumar, 2000)  
Nucleotide substitutions can be in the form of transitions (purine to purine/ pyrimidine to pyrimidine) or 
transversions (purine to pyrimidine and vice versa). α and β are the rates of the substitutions. 
Figure 2.10: A simplistic representation of a phylogenetic tree (adapted from Baum, 2008) 
The letters A-E represent the species. The branches of the most closely related species are connected by a 
node. All branches diverge from the most common ancestor to all the species.  
MCA= Most common ancestor 
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The methods for generating a phylogenetic tree can be divided into two general categories: 
distance and character based. The distance method is the more simplistic method. In this method, 
the distance of all pairwise combinations of sequences is calculated and a tree is assembled based 
on the calculated distances. Common examples of the distance method are the Unweighted pair-
Group Method with Arithmetic Mean (UPGMA) and the Neighbour Joining (NJ) algorithmic 
methods. The character-based methods, including Parsimony, Maximum Likelihood and Bayesian 
Inference, compares characters within each column of a multiple alignment, providing more 
information (Hall, 2011). Parsimony identifies the most likely tree to be the one that requires the 
fewest number of changes to explain the data in the alignment. Maximum likelihood searches for a 
tree that maximises the chance likelihood of observing the data using a model of evolution. 
Bayesian inference is a variant of maximum likelihood (Wright, 2017; Felsenstein, 1981). 
Bootstrapping is a statistical method used to test phylogenetic accuracy. It involves repeatedly 
building trees from subsamples of the dataset and calculating the frequency at which the parts of 
the tree are reproduced in each of the random subsamples. If a group is identified in every 
subsample tree, the bootstrap value would be 100%. If it is only found in half of the subsample 
trees, the bootstrap value will be 50% (Wright, 2017; Baldauf, 2003).  
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The aim of this study was to characterise two possible new HIV-1 C, D near full-length genome 
recombinant forms in South Africa. The following chapter describes the materials and methods used to 
achieve the aim and objectives. Figure 3.1 depicts the workflow that was followed to achieve the 
objectives.  
Figure 3.1: Flow chart showing the methodology process involved in the project 
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3.2. Reagents and equipment 
Several different reagents and equipment were used to achieve the objectives set out. The 
following tables identify all kits (Table 3.1), equipment (Table 3.2) and software (Table 3.3) that 
contributed to the completion of this study. 
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Table 3-1: Table of all reagents used 
Product/ kit Application Supplying company Catalogue 
number 
Benzonase Nuclease Pre-treatment step Merck, Germany 9025-65-4 
QIAmp viral RNA mini kit  RNA extraction Qiagen, Germany 52906 
Superscript IV First-strand 
synthesis system 
cDNA synthesis Invitrogen, USA 18091050 
GoTaq Long PCR mastermix PCR Promega, USA PRM0421 
KAPA HiFi HotStart ReadyMix 
PCR Kit 
PCR Kapa Biosystems, 
USA 
KK2601 
Nuclease free water All experiments Qiagen, Germany 145045078 
Seakem LE® agarose Agarose gels FMC  BioProducts,, 
USA 
50004 
GRgreen Staining dye Excellgen, USA EG-1008 
QiaQuick PCR purification Purification of PCR 
amplicons 
Qiagen, Germany 28106 
NucleoSpin gel and PCR 
clean up kit 
Gel extraction Machery-nagel, 
Germany 
740609.50 
BigDyeTM Terminator cycle 
sequence ready Kit 
Sequencing PCR Applied Biosystems, 
USA 
4 337 035 
5 x Sequencing buffer Sequencing PCR Applied Biosystems, 
USA 
4 305 603 
BigDye Xterminator 
purification kit 
Sequencing clean up Applied Biosystems, 
USA 
4 374 408 
NEB PCR cloning kit Cloning New England Biolabs, 
USA 
E1202 
LB agar Cloning Sigma Life Science, 
USA 
L2897 
LB broth Cloning Fluka BioChemika, 
USA 
61748 
GeneJet plasmid miniprep kit Plasmid purification ThermoFischer 
Scientific, USA 
K0502 
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Table 3-2: Table of equipment used  
Equipment Application Supplying Company 
Veriti thermal cycler PCR and cDNA synthesis Applied Biosystems, 
USA 




E-Gel® iBase™ Power System 
 
Gel electrophoresis Invitrogen, USA 
UV-ITEC Prochem Gel Dock System Gel visualisation Whitehead Scientific, 
SA 
Eppendorf Centrifuge 5415D All experiments Eppendorf, Germany 
Degicen 21R centrifuge Plate centifugation Ortoalresa, Spain 
ABI prism 3130XL automated DNA 
genetic analyser 
Sequencing Applied Biosystems, 
USA 
 
Table 3-3: Table of all the software used  













RIP Siepel A et al., 
1995 
https://www.hiv.lanl.gov/content/sequence/RIP/RIP.html  















Vilsker et al., 
2017 
https://www.genomedetective.com/  
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3.3. Ethical considerations 
Ethics permission for this study was obtained from the Health Research Ethics Committee (HREC) 
of Stellenbosch University under the protocol number N15/08/071 and was renewed annually (see 
appendix). The HREC complies with the South African National Health Act No.61 of 2003. This 
committee abides by the ethical norms and principles for research, established by the Declaration 
of Helsinki (World Medical Association, 2013), the South African Good Clinical Practices 
Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes 
2004 (Department of Health). 
3.4. Sample population and sample collection  
Between June 2008 and June 2015, the National Health Laboratory Services (NHLS), Virology 
Division, Tygerberg hospital received 7169 samples for routine HIV drug resistance testing. We 
received ethics permission for sequencing and phylogenetic analysis of these samples during this 
period. The majority of the samples were obtained from clinics / hospitals in the Eastern Cape, 
Western Cape and Gauteng, from both rural communities and large urban cities. From the 7169 
samples, ~6800 HIV sequences were obtained, of which 6156 sequences were used for 
phylogenetic analysis. The NHLS routinely sequences the partial pol region of the HIV genome to 
detect and determine the presence of drug resistance associated mutations (RAMs) against 
protease inhibitiors and reverse transcriptase inhibitors. From this cohort, 161 non-subtype C 
viruses were identified based on sequencing and phylogenetic analysis of the partial pol region 
(~1,4kb; HXB2 positions ~2151-3334) of the HIV genome. In 2011 four possible unique C, D 
recombinants were first noticed within this cohort. These recombinants had similar breakpoints in 
the pol gene. By the end of 2015 there were 30 C, D recombinants within the non-subtype C cohort 
(S. Engelbrecht, personal communication). The samples were coded to hide true patient identity. 
The code is generated by using the province abbreviation and an assigned numerical value. For 
example, EC148 originated from the Eastern Cape and is number 148 in the cohort. Recombinant 
Identification Program (RIP), Molecular Evolutionary Genetics Analysis (MEGA), jumping profile 
Hidden Markov Model (jpHMM), Context-based Modelling for Expeditious Typing (COMET) and 
phylogenetic analysis in MEGA were used to identify the possible subtype of the virus based on 
sequences obtained for this region of the genome. 
We selected two of these possible C, D recombinants from different provinces and at different time 
points for further characterisation. The selection of these samples were based on sample volume 
and availability.  
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3.5. Nucleic acid extraction 
3.5.1. DNA extraction 
Human genomic DNA from sample EC148 was extracted with the QiaAmp DNA kit (Qiagen, 
Germany) using the vacuum method. The genomic DNA was extracted from 140µl of PBMCs. The 
process was performed according to the manufacturer’s instruction manual. Briefly, the DNA was 
collected on the silica membrane of the spin column during the vacuum step. The DNA 
subsequently underwent two wash steps using buffers AW1 (Wash buffer 1) and AW2 (Wash 
buffer 2), removing any residual contaminants. The DNA was eluted with an elution buffer (10 mM 
TrisCl; 0.5 mM EDTA (Ethylenediaminetetraacetic acid); pH 9.0) and the extracted DNA was 
collected in a 1,5ml microcentrifuge tube. The extracted DNA was stored at -20°C for later use. 
3.5.2. RNA extraction 
A pre-treatment step using Benzonase was used to improve the quality of viral RNA. Benzonase 
(Merck, Darmstadt, Germany) is an endonuclease originating from Serratia marcescens. It aims to 
improve cDNA synthesis efficiency by removing circulating nucleic acid in human plasma 
(Benzonase Brochure, Merck, Germany). The pre-treatment step is performed by adding 10µl of 
the enzyme solution to 140µl of plasma sample and is incubated at 37oC for 30 minutes. To 
inactivate the Benzonase nuclease, 20µl of 2mM EDTA buffer is added to each sample and the 
sample is incubated on ice for 10 minutes. Thereafter, RNA extraction is done as per normal 
instructions.  
Viral RNA was extracted from 140µl of plasma using the QiaAmp RNA kit (Qiagen, Germany). The 
kit combines the properties of a silica membrane and the speed of a centrifuge to effectively extract 
purified RNA. All centrifuge steps were performed in an Eppendorf 5415D centrifuge (Merck, USA) 
at 13000 x g (gravitational force). The spin protocol was followed as per the manufacturer’s 
instructions. Carrier RNA was used in the process to enhance the binding of the nucleic acid to the 
silica membrane and to reduce the chance of RNA degradation (QiaAmp RNA kit handbook, 
Qiagen). In short, the sample is lysed under denaturing conditions to inactivate RNases. The salt 
and pH conditions in the lysate ensures that substances in the sample, other than RNA, are not 
retained in the membrane. The RNA binds to the silica membrane of the spin column and 
undergoes two wash steps using buffers AW1 and AW2 to ensure that any residual contaminants 
are removed. Finally, the RNA is eluted with 30µl of elution buffer and the purified RNA is collected 
in a 1,5ml microcentrifuge tube (Thermofischer Scientific, USA) and stored at -800C. The lower the 
volume of elution buffer used, the more concentrated the purified nucleic acid will be. 
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3.6. cDNA synthesis 
The extracted RNA was reverse transcribed to complimentary DNA (cDNA) using the Superscript 
IV First Strand Synthesis system (Invitrogen, USA). This kit makes use of a reverse transcriptase 
that is purified from Escherichia coli (E.coli) and is modified to increase its effectivity (Invitrogen 
Superscript IV handbook). Briefly, a specific primer binds to the 3’ end of the template RNA and the 
reverse transcriptase generates a cDNA strand by adding deoxynucleotide bases resulting in a 
RNA-DNA hybrid molecule. The RNA strand of the hybrid is degraded and a second, 
complimentary strand of DNA is synthesised in place of it, resulting in a double stranded cDNA 
molecule. The LOW2 primer (TGAGGCTTAAGCAGTGGGTTTC , Gao et al., 1998) was used for 
this reaction. The protocol was followed as per the manufacturer’s instructions with one 
modification (Table 3.4). An extra incubation step at 550C for ten minutes was included before the 
inactivation incubation. This was done in an attempt to increase the success of the assay. The 
thermocycler conditions were carried out in a Veriti thermocycler (Applied Biosystems, USA). The 
cDNA was stored at -200C and used for PCR. 
Table 3-4:cDNA synthesis reaction assembly 
Reagent Final Conc. Volume  Temperature (°C) Time (minutes) 
Primer (Low 2) 0.1µM 2   
10mM dNTP mix 0.5mM each 1   
RNA template <5 µg 10   
  13 65 5 
5X buffer 1 x 4   
100mM DTT 5mM 1   
Ribonuclease (OUT) 2.0 U/µL 1   
SSIV  1   
  7   
   55 10 
   55 10 
   80 10 






Total Volume  11   
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3.7. Nucleic acid quantification 
The Nanodrop (Thermofischer, USA) technology was used to spectrophotometrically determine the 
concentration of DNA in each sample. Nucleic acid quantification is measured by calculating the 
nucleic acid concentration at a wavelength of 260nm. One microliter of the sample was placed on 
the pedestal to determine the DNA concentration per microliter. The nanodrop reading provides 
measurements of DNA concentration as well as DNA purity. The concentration of DNA is recorded 
as ng/µl. Pure DNA falls between the range of 1.7 and 1.9. Values lower than 1.7 indicate protein 
contamination while values higher than 1.9 indicated the presence of RNA in the sample 
(Desjardins and Conklin, 2011). 
3.8. Polymerase chain reaction (PCR) 
PCR is a molecular assay that makes use of an enzyme to make multiple copies of a DNA strand 
(Saiki et al., 1988; Mullis et al., 1986). One of the enzymes frequently used for PCR is extracted 
from the organism Thermus aquaticus and is commonly known as Taq (Saiki et al., 1988). The 
Promega GoTaq long PCR mastermix (Promega, USA) was used in this study. The mastermix 
contains all components required to perform long-range PCRs. These components include an 
optimized buffer, dNTPs, MgCl2 and an optimized hot start enzyme blend for long-range PCR. The 
forward and reverse primers, nuclease free water and the DNA template are added to a reaction 
tube containing the mastermix to perform a reaction. Briefly, the DNA is heated to separate the 
double strands and generate single strands. The primers bind to their corresponding nucleotide 
bases on the template. Thereafter the enzyme (Taq polymerase) binds to the primer and initiates 
the addition of complimentary nucleotide bases to the template DNA, generating a double stranded 
DNA molecule. This is repeated to generate multiple copies of the template DNA. The PCR 
process is performed in a thermocycler using varying temperatures for the different steps. The 
denaturation step requires a high temperature to separate the double stranded DNA molecule. The 
temperature is then lowered for an annealing step in which the primer binds to the single stranded 
DNA template. Finally, an elongation step, at a slightly higher temperature, involves the 
incorporation of the nucleotide bases. All PCRs were carried out in a Veriti thermocycler (Applied 
Biosystems, USA). 
3.8.1. NFLG PCR amplification strategy 
In an attempt to amplify the near full-length genome (NFLG) of HIV-1 (HXB2 location 634 – 
9612bp), the amplification was performed in two rounds of PCRs. The first round PCR targeted the 
amplification of the NFLG (8957kb) and the second round PCRs targeted the amplification of two 
overlapping fragments: of a gag-vpu fragment (5455bp) and a pol-3’LTR fragment (4909bp) 
(Figure 3.2). A combination of an in-house and an unpublished protocol was followed for both 
rounds of PCR. All fragments were amplified using the Promega GoTaq Long PCR 2X mastermix. 
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Primers were diluted to 10µM. Each reaction contained 25µl of the reaction mix, 16µl of nuclease 
free water, 2µl of each primer and 5µl of template, equating to a final volume of 50µl. Negative 
controls were included with test reactions. Each negative control was comprised of the same 
components as the test reactions with the exception of 5µl of template. 5µl of nuclease free water 
was added to the negative control reaction in place of the template.  
The PCRs include a number of heating and cooling steps required for successful amplification of 
the target fragment/s (Table 3.5). The thermocycling conditions for the first and second round 
PCRs were the same with the exception of the extension times. The first round PCR required a 9 
minute extension time whereas the second round PCRs only required 6 minutes. The extension 
time is calculated as 1 minute per kb.   
Figure 3.2: PCR amplification strategy used for first and second round PCRs  
The red bar represents the first round PCR fragment and the blue bars represent the second round 
PCR fragments. The blue bar on the left represents the gag-vpu fragment and the one to the right 
represents the pol-3’LTR fragment. Adapted from Gao et al., 1996 Grossman et al., 2015 and Fang et 
al., 1996. 
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Table 3-5: Thermocycler conditions for first and second round PCR 
Min=minutes; Sec=seconds 
Step Temperature (0C) Time No. of cycles 
Initial denaturation 95 3    min. 1 
Denaturation 98 20  sec. 30 
Annealing 65 30  sec. 
Extension 72 9/6   min. 
Final extension 72 5  min. 1 
Soak 4 Indefinite 1 
 
3.8.2. First round PCR 
The first round PCR reaction targeted the amplification of a 8957bp NFLG of HIV-1 (HXB2 position 
634-9612) using the UP1A and LOW2 primer pair (Table 3.6) described by (Gao et al., 1996). The 
first round PCR amplification strategy was performed according to the protocol described by (Gao 
et al., 1998). 
Table 3-6: Primers used for first round of the NFLG amplification of HIV-1 
Primer orientation Primer name Oligonucleotide sequence HXB2 position 
Forward UP1A 5’AGTGGCGCCCGAACAGG3’ 634  650 
Reverse LOW2 3’TGAGGCTTAAGCAGTGGGTTTC5’ 9612 9591 
Expected size 8957bp 
 
3.8.3. Second round PCR 
The second round PCRs targeted the amplification of the HIV-1 gag-vpu fragment (first 5455bp of 
the NFLG) and the pol-3’LTR fragment (last 4909bp of the NFLG).The first round PCR product was 
used as the template the second round PCRs. The primers used for the amplification of the gag-
vpu fragment were 0776F and 6231R (Grossmann et al., 2015) (Table 3.7). This region of the 
genome includes the gag, pol, vif and vpr genes of the HIV genome. The primers used for the 
amplification of the pol-3’LTR fragment were FGF46 and FGR95 (Fang et al., 1996) (Table 3.8). 
This region is from position 9557 to position 2564 relative to the HXB2 genome. The genes 
covered in this region of the genome are the partial integrase, vif, vpr, vpu env and nef genes. 
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Table 3-7: Primers used for amplification of the pol-vpu fragment  





Oligonucleotide sequence HXB2 
position 
Forward FGF46 5’GCATTCCCTACAATCCCCAAAG3’ 46484669 
Reverse FGR95 3’GGTCTAACCAGAGAGACCCAGTACAG5’ 9557 9532 
Expected size 4909bp 
3.8.4. Second round PCRs using Kapa HiFi 
The Kapa HiFi HotStart Ready Mix PCR kit (Kapa Biosystems, USA) was used to re-amplify the 
gag-vpu and pol-3’LTR fragments of sample WC416 in an attempt to obtain better quality 
sequences for a region of the genome that was difficult to sequence. The kit makes use of a novel 
B-family DNA polymerase that is engineered to have increased affinity for DNA (Kapa HiFi 
handbook). In the ready mix kit, the KAPA HiFi hotstart DNA polymerase is provided in a 2X 
readymix, containing all reaction components except primers, water and template. The same 
second round PCR primers (0776F and 6231R; FGR95 and FGF46) were used. The reaction was 
made up to 50µl and comprised of 25µl of the 2X readymix, 19µl of nuclease free water, 2.5µl of 
each primer and 1µl of template .The thermocycling conditions for this kit differed to the conditions 
used for the GoTaq long PCR mastermix kit (Table 3.9).  







Expected size 5455bp 
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Table 3-9: Thermocycling conditions for second round PCR using KAPA HiFi 
Step Temperature (0C) Time No. of cycles 
Initial denaturation 95 3 minutes 1 
Denaturation 98 20 seconds 30 
Annealing 65 30 seconds 
Extension 72 3 minutes 
Final extension 72 5 minutes 1 
Soak 4 Indefinite 1 
3.9. Agarose gel electrophoresis 
The E-gel (Life technologies, USA) agarose gel electrophoresis system is a bufferless system for 
gel electrophoresis analysis of DNA samples. The E-gel system contains a pre-cast agarose gel 
that includes electrodes and is packaged in a disposable, ultraviolet (UV) transparent cassette. 
These gels are run in a unique design that is a base and power supply in one device.  
The E-gel was used to determine the size of the amplified DNA PCR products. A 0.8% gel was 
used and run at a pre-set voltage and time. Once the run was complete, the gel was visualised 
under a UV light at a wavelength between 260 and 320 nm and a gel photo was taken with the 
Syngene™ GeneGenius computer system (Synoptics Ltd.,United Kingdom). 
When the E-gel system wasn’t available, agarose gels were made manually. A 0.8% agarose gel 
was made up by combining 0,8 grams of agarose powder (Seakem LE® agarose; USA) with 
100ml 1X TAE (Tris-acetate-EDTA) buffer (0.04 M Tris acetate, 0.001 M EDTA). A lower 
percentage gel results in larger pore size in the gel. This is preferred for large fragments as it 
allows for easier movement of the large fragment. The gel was cooled before 10µl of GRgreen 
staining dye (Excellgen, USA) was added to the liquid solution. The solution was poured into a 
casting tray and allowed to set before samples could be loaded. These gels were run at 80 volts for 
1 hour. 
For both types of gels, a 1kb DNA ladder (Promega, USA) was used to determine the size of the 
fragments on the gel. The gels were analysed with the Syngene™ computer system (Synoptics 
Ltd., United Kingdom). 
3.10. PCR product purification 
3.10.1. Standard PCR purification 
The QiaQuick PCR purification kit (Qiagen, Germany) was used to purify the second round PCR 
products. This process removes the impurities that may be present in the DNA. The purification 
Stellenbosch University  https://scholar.sun.ac.za
 
34 
was done according to the manufacturer’s instructions. Briefly, the DNA is first bound to the 
membrane of a spin column by centrifugation at 13 000 x g in an Eppendorf 5415D centrifuge 
(Merck, USA). Thereafter, the DNA undergoes two wash step with buffer PE (wash buffer) and 
finally the purified DNA is eluted with 30µl elution buffer. The purified DNA is stored at -200C until it 
is to be used again. 
3.10.2. Gel extraction 
In instances where the second round PCR products displayed non-specific bands on the gel, 
indicating the amplification of fragments that were not targeted, gel extraction was done to excise 
the desired fragment only. The NucleoSpin® gel and PCR clean up kit was used for the extraction 
(Machery-Nagel, Germany). The target fragment was cut out of the gel with the aid of a UV dock 
system that allowed for visualisation of the fragment in the gel. The excised piece of gel containing 
the target fragment was mixed with binding buffer NTI and heated at 50°C for 5-10 minutes until the 
gel completely dissolved. The DNA was bound to the NucleoSpin column by centrifugation at 
11 000 x g for 30 seconds in an Eppendorf 5415D centrifuge (Merck, USA). The DNA underwent 
two wash steps with buffer NT3 and was eluted with 30µl of elution buffer NE. The collected eluted 
DNA was stored at -20°C for further use. 
3.11. Molecular cloning 
3.11.1. Cloning reactions 
HIV sequencing results of sample EC148 identified quasispecies as indicated by variability within 
the env region. Quasispecies is a steady-state population of sequences variants derived from a 
master sequence through mutations (Domingo et al., 2012; Gross et al., 2014). In an attempt to 
obtain single copy viral sequences, the 3’LTR fragment was cloned. The NEB PCR cloning kit (with 
NEB-10 beta competent E.coli cells) (New England BioLabs, UK) was used. The protocol 
comprised of three steps: ligation, transformation and plating. Briefly, in the ligation step the insert 
was mixed with the vector and cloning mix 1 and 2. The ligation reaction was incubated at room 
temperature for 15 minutes, followed by incubation on ice for 2 minutes. Two microliters of the 
ligation reaction was added to 50µl of competent E.coli cells and then incubated on ice for 20 
minutes. Thereafter, the cells were heat shocked at 42°C for 30 seconds. Nine hundred and fifty 
microliters (950µl) of NEB stable outgrowth medium was added to the cells and was shaken at 
37°C for 1 hour. 50µl of the outgrowth was spread on ampicillin selection plates and incubated at 
37°C overnight. 100µl and 200µl volumes were also spread on separate plates to determine the 
optimal volume for bacterial growth.  
The LB agar for the plates was made up by mixing 10,5g of lysogeny broth (LB) (Lennox broth with 
low sodium chloride concentration) agar into 300ml of distilled water. The mixture was autoclaved 
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and once cooled, 150µl of ampicillin (Sigma, USA) was added. Twenty-five millilitres (25µl) of the 
LB agar was dispensed into each plate and allowed to cool until it set.  
A colony PCR targeting the amplification of the pol-3’LTR was done on one colony from each plate. 
Instead of adding 5µl of template, a single colony was lightly touched with a pipette tip, which was 
consequently swirled into a PCR reaction mastermix before undergoing the PCR thermocycling 
conditions as described in Table 3.9.  
The cloning PCR products were run on agarose gels. If the target fragment was successfully 
amplified, it indicated that the cells in that colony successfully took up the insert fragment. In such 
instances, the same colony used for the PCR was cultured by transferring it into 5ml of LB broth 
containing ampicillin. The broth containing the colony was shaken at 37°C overnight.  
3.11.2. MiniPrep 
The GeneJet MiniPrep kit (Thermoscientific, USA) was used to purify the plasmid DNA obtained 
from the cloning procedure. The cells containing the plasmid were harvested by centrifugation for 2 
minutes at 13000 x g using the Eppendorf 5415D centrifuge (Merck, USA). The supernatant was 
decanted and the remaining pellet was purified as per the manufacturer’s instructions. Briefly, the 
cells were re-suspended, lysed, neutralised and centrifuged. The resulting supernatant was 
transferred to a spin column and centrifuged to bind the DNA to the spin column membrane. The 
column was washed twice with 500µl wash solution followed by a dry spin to remove any residual 
wash buffer. Finally, the DNA was eluted with 30µl of elution buffer and stored at -20°C.  
3.12. Sanger Sequencing 
3.12.1. Sequencing PCR  
The sequencing PCRs were performed using the BigDyeTM Terminator Cycle Sequencing Ready 
Reaction kit, version 5 (Applied Biosystems, USA). The manufacturer’s instructions were slightly 
optimised. Instead of using 1µl of the reaction mix and 6µl of 5X buffer, 0,5µl and 3µl was used, 
respectively. The volumes were halved as a preferred protocol showed it to yield the same quality 
of results as the recommended volumes. Firstly, a reaction mix consisted of 4.5µl nuclease free 
water, 0.5µl reaction mix and 3µl of 5X EDTA buffer. Eight microliters (8µl) of the reaction mix was 
added to each well. One microliter (1µl) of primer and 1µl of DNA sample was added to each well 
separately resulting in a total volume of 10µl. The wells were sealed and spun down at 13 000 x g 
for 2 minutes on an Eppendorf 5415D centrifuge (Merck, USA). The sequencing PCR included one 
cycle of denaturation at 960C for 10 seconds followed by 25 cycles of annealing and elongation at 
550C for 7 seconds and 600C for 4 minutes, respectively. A final hold / soak step was included at 
40C for an indefinite time. 
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3.12.2. Sequencing clean up 
The BigDye X-TerminatorTM Purification Kit (Applied Biosystems, USA) was used to remove 
impurities that may have accumulated from the sequencing PCR reaction. The manufacturer’s 
protocol was followed. Briefly, a mixture of 49.5µl of Sam’s solution and 11µl of Exterminator was 
prepared per reaction. Fifty-five microliter of the mixture was added to each well. The plate was 
shaken for 30 minutes before being centrifuged for two minutes at 13 000 x g on a Digicen 21R 
centrifuge (OrtoAlresa, Spain). The plates were sequenced using the automated ABI3730xl 
sequencing machine (Applied Biosystems, USA) at the Stellenbosch University Central Analytic 
Facility (CAF; https://www.sun.ac.za/english/faculty/science/CAF).  
3.13. Sequencing analyses 
The generated raw ABI files were imported into Sequencher version 5.0 (GeneCodes corporation, 
USA). The software determined the quality of the sequence and allocated a percentage to each 
sequence based on the quality. Firstly, the quality of the sequences were assessed and sequences 
of less than 85% quality were removed. The ends of the sequences were trimmed to improve the 
read quality. Thereafter, a contig was generated and aligned to the HXB2 reference sequence 
(GenBank accession number K03455). This gave an indication of the position of the fragment 
according to the HIV genome. The sequences were read and the contig was exported as FASTA 
format for further analyses. 
3.14. Quality control 
The quality of the exported sequences were assessed in the HIV LANL quality control tool 
(https://www.hiv.lanl.gov/content/sequence/QC/index.html). The tool uses a number of tests to find 
common problems with the query sequence. The analyses determines the subtype, most similar 
database sequence, phylogenetic trees for each and all sequences with subtype references, the 
number of stop codons and frameshift mutations and hypermutations within the query sequence. 
The quality control tool generates a true indication of the quality of the sequences and it shows 
areas of the sequences that have problems and this allows for the region to be re-checked.  
3.15. HIV subtyping programmes 
Online HIV subtyping programmes determine the possible subtype of the viral sequence of the 
samples. Each tool uses a different algorithm to assign a subtype to the virus. 
jpHMM (http://jphmm.gobics.de/submission_hiv), RIP (https://www.hiv.lanl.gov/content/sequence/R
IP/RIP.html) and REGA (http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-
hiv/typingtool/) were used, as they are the most suitable programmes for determining recombinant 
subtypes. jpHMM is a probabilistic approach, it doesn’t align the input sequence to the alignment of 
possible subtypes as a whole, but it instead does this in local segments. This is useful for 
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identifying the subtype of recombinant viruses. REGA constructs a multiple sequence alignment 
with the query sequence and subtype sequences and trees are constructed from this alignment 
using the HKY distance method in PAUP* software (Swofford, 2002). 
3.16. Reference sequences 
The partial genome and full length genome reference sequences needed to generate a multiple 
sequence alignment with the query sequences were obtained from the HIV LANL database 
(www.hiv.lanl.gov). The references were selected from the curative alignments page. Subtype 
reference alignment type was selected and all group M (without recombinants) reference 
sequences were downloaded and used. This set of reference sequences was used for all 
phylogenetic inferences.  
3.17. Multiple sequence alignment 
The reference sequences and sample query sequences were imported into Geneious version 
11.1.3 (Kearse et al., 2012) for multiple sequence alignments using the MAFFT plugin (Katoh et 
al., 2017). MAFFT aligned the reference sequences to the sample sequence and identified the 
regions of homology between the sequences. The alignment was trimmed at the beginning and 
end, according to the query sequence length, to ensure that all sequences were the same length. 
The alignment was exported as .meg and .fasta files. 
3.18. Model test 
A model test was conducted on each dataset to determine which evolutionary model to use in 
inferring the phylogenetic trees. The model test was done in MEGA version 6 (Tamura et al., 
2013). From the table of results generated by the model test, the model with the lowest Bayesian 
Information Criterion (BIC) value was selected as the best model for the dataset.  
3.19. Inferring phylogenetic trees 
The multiple sequence alignment generated using the MAFFT plug-in in Geneious version 11.1.3 
was used to construct a phylogenetic tree in MEGA. Maximum Likelihood phylogenetic trees were 
constructed for the datasets by selecting the “Construct/test Maximum Likelihood Tree” option 
under the phylogeny tab in MEGA. The test of phylogeny option was set to Bootstrap method and 
the number of replicates were set to 1000 for accuracy. The specific model that correlates to the 
outcome of the model test was selected for each dataset. All other options were left at default. 
Phylogenetic trees were inferred for the complete genomes as well as for each region of the 
genomes that identified as different subtypes.  
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4.1. Demographics of study samples 
Thirty (30) partial HIV-1 pol sequences (HXB2 position 2151-3334) obtained from samples in the 
non-subtype C cohort identified as possible C, D recombinants (Table 4.1). Two samples were 
selected for further NFLG characterisation based on sample availability and sample volume. The 
first is a PBMC sample from a 31 year old female from the Eastern Cape, obtained in 2012 and the 
second is a plasma sample from a 34 year old female from the Western Cape obtained in 2014. 
The samples were collected at different time points and at different geographical regions within the 
country, therefore they are not epidemiologically linked. The samples were also of different nucleic 
acid types. Genomic proviral DNA was extracted from the PBMC sample and viral RNA from the 
plasma sample. Multiple samples were used to try obtaining NFLG amplification however, these 
samples did not amplify and only EC148 and WC416 was successfully amplified and were 
subsequently used for further characterisation. 
Table 4-1: Sample demographics of all 30 possible C, D recombinants in non-subtype C cohort 
Highlighted samples were selected for characterisation of NFLGs 
Patient Code Specimen date Age Gender Province 
GT434 07 May 2008 25 F Gauteng 
GT764 29 April 2009 36 F Gauteng 
EC013 22 June 2009 33 M Eastern Cape 
GT1112 17 February 2010 56 F Gauteng 
WC123 17 February 2011 36 F Western Cape 
GT1608 25 March 2011 57 F Gauteng 
EC045 23 June 2011 28 F Eastern Cape 
WC183 12 August 2011 38 F Western Cape 
EC134 30 November 2011 32 F Eastern Cape 
EC148 12 January 2012 31 F Eastern Cape 
EC199 19 March 2012 31 F Eastern Cape 
EC212 12 April 2012 9 Unknown Eastern Cape 
EC284 12 June 2012 29 F Eastern Cape 
EC532 12 February 2013 36 F Eastern Cape 
EC746 13 August 2013 51 M Eastern Cape 
EC818 11 October 2013 32 F Eastern Cape 
Stellenbosch University  https://scholar.sun.ac.za
 
40 
EC852 05 November 2013 32 M Eastern Cape 
EC1031 26 February 2014 9 M Eastern Cape 
WC416 05 March 2014 34 F Western Cape 
EC1097 31 March 2014 28 F Eastern Cape 
Pr136 01 April 2014 Unknown Unknown Unknown 
EC1128 14 April 2014 4 F Eastern Cape 
EC1143 23 April 2014 45 F Eastern Cape 
Pr147 03 June 2014 Unknown Unknown Unknown 
WC500 18 July 2014 36 F Western Cape 
EC1406 08 October 2014 2 M Eastern Cape 
WC539 20 October 2014 17 M Western Cape 
EC1456 13 November 2014 26 F Eastern Cape 
EC1484 24 November 2014 28 F Eastern Cape 
EC1562 29 January 2015 38 Unknown Eastern Cape 
4.2. Nucleic acid quantification of WC416 and EC148 
The concentration of DNA was determined after the cDNA synthesis step for sample WC416 and 
after extraction of sample EC148 (Table 4.2).  
Table 4-2: Sample DNA concentrations and purity 
Sample name  ng/µl 260/280 260/230 
WC 416 95.3 1.81 1.05 
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4.3. NFLG amplification of WC416 and EC148 
Agarose gel photographs of the first round PCRs were not included due to the bands usually not 
being visible on the gels. The following gel photographs are of the second round PCRs. The gag-
vpu and pol-3’LTR fragments were successfully amplified for sample WC416 using Promega 
GoTaq Long PCR (Figure 4.1) and with KAPA HiFi hotstart ready mix (Figure 4.2). Samples 
GT1112, EC818, Pr136, EC1143 and 118037 were not successful in amplifying both fragments 
and were excluded further from the study (Figure 4.1). The gag-vpu and pol-3’LTR fragments were 
successfully amplified for EC148 (Figure 4.3). With the overlapping fragments being amplified for 
WC416 and EC148, the NFLG was obtained for both samples. 
 
Figure 4.1:  Amplification of gag-vpu and pol-3’LTR for sample WC416 
The bands in the red lane represent the amplification of WC416. Figure A shows the gag-vpu amplicon 
(5455bp) in lane 3. Figure B shows the pol-3’LTR amplicon (4909bp) in lane 3. Both fragments correspond 
with the expected fragment size on the marker. A 0.8% gel was used. 
Lane 1 - GT1112, lane 2 - EC818, lane 3 – WC416; lane 4 - Pr136; lane 5 - EC1143, lane 6 – 118037.  
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Figure 4.3: Amplification of gag-vpu and pol-3’LTR for EC148 
Figure A shows the gag-vpu amplicon (5455bp). Figure B shows the pol-3’LTR amplicon (4909bp). Both 
amplicons align with the expected size on the 1kb DNA marker. A 0.8% gel was used.  
 
Figure 4.2: Amplification of gag-vpu and pol-3’LTR for WC416 using KAPA  
The gag-vpu amplicon (5455bp) is seen in the left lane; the pol-3’LTR fragment amplicon (4909bp) in the 
middle lane and the 1kb DNA ladder in the third lane. Both bands correspond with the desired fragment size. 
T. A 0.8% gel was used. 
A 
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4.4. Cloning of pol-3’LTR fragment of sample EC148  
A cloning colony PCR was done to determine if the fragment was inserted in the plasmids. 
Amplification of the pol-3’LTR fragment was successful, indicating that the fragment was inserted 
in the plasmid (Figure 4.4). The correct size DNA band fragments (4909bp) were gel extracted and 
purified for further downstream processing. 
The colonies that had positive colony PCR results were cultured and the DNA containing the target 
fragment was extracted. This DNA was sequenced using primers specific for the insert fragment; 
however, the sequencing was not successful. In order to obtain the DNA of the insert fragment that 
was successfully cloned, the bands containing this fragment in Figure 4.4 were gel extracted and 
purified. The resulting DNA was successfully sequenced. 
 
 
4.5. NFLG Sequencing of EC148 and WC416 
The HIV-1 NFLG for both samples were successfully sequenced. A 8893bp and a 7720bp NFLG 
were generated for the viruses of samples WC416 and EC148, respectively. Sequences were 
imported into the Sequencher software where the quality of each was assessed. The ends and 
beginning of the sequences were trimmed to increase the overall quality of the sequence. 
Sequences with quality values below 85% were removed. A contig of all qualifying sequences was 
generated for each sample. 
Figure 4.4: Cloning PCR of pol-3’LTR of EC148 
The pol-3’LTR amplicons (4909bp) were successfully amplified in lanes B and C. The amplicons in these 
lanes corresponded to the expected band size of the marker. The amplification in lane A was not successful 
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The sequences were aligned to reference sequence HXB2 using Sequencher version 5 to decipher 
which portions of the genome they represent. Sample WC416 was successfully sequenced from 
position 826 – 9719 according to HXB2 numbering, generating a 8893bp NFLG (Figure 4.5). 
Sample EC148 was sequenced from HXB2 position 779 to 8499, creating a 7720bp NFLG (Figure 
4.6). 
 
Figure 4.5: NFLG contig of sample WC416 
The green and red arrows represent forward and reverse primers, respectively. The green bar at the bottom 
of the image indicates the region of the genome that was sequenced with reverse and forward primers. 
Regions of blue represent the portions of the genome that was sequenced with either a reverse or forward 
primer. 
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Figure 4.6: NFLG contig of sample EC148 
Contig of all sequences for the sample assembled into a contig and aligned to the HXB2 reference 
genome. Red and green arrows represent reverse and forward primers used. The green bar at the 
bottom of the image indicates the region of the genome that was sequenced with reverse and forward 
primers. Regions of blue represent the portions of the genome that was sequenced with either a 
reverse or forward primer 
 
4.6. Analyses of HIV-1 sequences  
After contigs were generated for each sample, the sequences were read to verify any 
discrepancies that may have resulted from the sequencing reactions. The sequences were 
scanned for bases that could not be accurately identified by the Sequencher software. This was 
done by analysing the corresponding chromatograms. The chromatograms were analysed to 
manually assign a nucleotide to the ambiguous bases, where possible. Once the NFLG sequences 
were checked, the sequence was uploaded for quality control. Discrepancies identified by the 
quality control tool were once again checked and verified in Sequencher. This process was 
repeated until there were no or minimal discrepancies in the quality control results.  
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4.7. Quality assessment of sequences 
The quality control tool was used to determine the overall quality of the sample sequence. The 
quality control results for sample WC416 detected one stop codon and one frameshift mutation 
within the sequence. No hypermutations were detected and there was a 0.1% of non-ACGT 
content. The RIP subtyping used by the quality control tool identified the sample as an A1, C, D 
recombinant and the BLAST result showed the sample sequence to be most similar to a Tanzanian 
subtype C sequence from 1992 (Accession number A253310). The quality control results for 
sample EC148 detected 7 stop codons, 6 frameshifts and possible hypermutations. There was a 
0.0% of non-AGCT content within the sample sequence. RIP identified the sample as an A1, C, D 
recombinant. The sequence most closely related to the sample sequence was detected by BLAST 
to be a subtype C reference sequence from Botswana in 1992 (Accessioin number KY658708).  
4.8. Subtype identification with online subtyping programmes 
The jpHMM, REGA and RIP online subtyping programmes identified the possible subtype of each 
sample. The results from each of these tools are given below.  
The results obtained from each subtyping tool were consistent for WC416. Each identified the 
sample as a complex A, C, D recombinant (Figure 4.7). All three results identified subtype A and C 
in the gag; D and C in the pol; C in the vif, vpr and vpu; C and A in the env and subtype A and C in 
Figure 4.7: Online subtyping tools results for WC416 
Figure A represents the RIP similarity plot. The bar at the top of the figure represents the different subtypes 
identified in the sample; the x axis indicates the distance in nucleotides and the y axis represents the 
similarity. Pink represents subtype C, brown subtype D and red subtype A. Figure B represents the jpHMM 
result. The figure shows the distribution of the different subtypes in the viral genome. Subtype A is seen as 
red, subtype C as brown and subtype D as pink. Figure C represents the REGA results. The figure shows the 
distribution of the different subtypes within the viral genome. Subtype A is seen as red, subtype C as brown, 
subtype D as pink and a region of uncertainty is seen as green. All three results identify the sample as a 
complex A, C and D recombinant. 
Stellenbosch University  https://scholar.sun.ac.za
 
47 
the nef and 3’LTR.  
All three online subtyping tools identified EC148 as a complex recombinant of subtypes A, C and 
D, with jpHMM and REGA identifying regions of additional subtypes (Figure 4.8). RIP identified the 
sample as a combination of subtypes A, C and D (Figure 4.8A). jpHMM results showed subtypes 
A, C and D in the gag, C, D and K in the pol; K and C in the vif  and subtype C in the vpr, vpu and 
env (Figure 4.8B). jpHMM did not detect subtype A in the env as RIP and REGA did. To query this 
result, just the env region of the NFLG was analysed in jpHMM. Figure 4.10 shows the jpHMM 
result for the extracted region and it identifies subtype A in the env. The REGA tool assigned 
subtypes A, C and B in the gag; C, B, D and G in the pol; C in the vif, vpr, vpu and subtype A and 
C in the env. The REGA analysis image (Figure 4.8 C) is the approximate recombination pattern 
without bootstrap confidence. Figure 4.9 illustrates the results of the REGA bootscan analysis and 
it shows that only subtypes A, C and D are detectable at over 70% support.  
 
Table 4-3: Summary of the outcomes from each online subtyping tool for WC416 and EC148 
Genotyping tool WC 416 EC148 
RIP A,C,D,C,A,C,A A,C,D,C,A 
jpHMM A,C,D,C,A,C,A A,C,D,C,K,C 
REGA A,C,D,C,A,C,A A,C,D,C,A 
 
Figure 4.8: Online subtyping tool results for EC148 
Figure A represents the RIP result. it identifies subtype A, C and D in the sample. The bar at the top of the 
figure represents the different subtypes identified in the sample; the x axis indicates the distance in 
nucleotides and the y axis represents the similarity. Pink represents subtype C, brown subtype D and red 
subtype. Figure B represents the jpHMM result. The figure shows the distribution of the different subtypes in 
the viral genome. Subtype A is identified as red, subtype C as brown, subtype D as pink and subtype K as 
purple. Figure C represents the REGA results. The figure shows the distribution of the different subtypes 
                     
      







4.9. Choosing an evolutionary model 
A model test was conducted to determine which nucleic acid substitution model best fit each 
dataset. The test was performed on each dataset that would be used to infer a phylogenetic tree. A 
phylogenetic tree was inferred for each recombinant segment. For sample WC416, 11 
phylogenetic trees were inferred - one for the NFLG and 10 for each portion of the NFLG that 
identified as a distinct subtype by the jpHMM result. Each portion is described as a fragment. For 
sample EC148, 8 phylogenetic trees were inferred – 1 for the NFLG and 7 for each subtype. The 
Figure 4.9: REGA bootscan analysis result for EC148 
Peaks above the red dotted represents results that are detected at over 70% bootscan 
support. The y axis represents the support value and the x axis indicates the nucleotide 
position. 
Figure 4.10: jpHMM result for only the vif, vpr, vpu and env 
The vif, vpr, vpu and a portion of the env identified as subtype C while the remainder of the env identified as 
subtype A. 
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model tests used for each of the generated trees is shown in Table 4.3 and Table 4.4. The model 
with the lowest BIC value was selected as the model most suited for the dataset.  
Table 4-4: Model tests used to generate each tree for WC416 
Fragment Size of fragment (bp) HXB2 position Selected model 
WC416 
NFLG 8736 826-9562 GTR+G+1 
1 369 826-1195 HKY+G 
2 999 1197-2196 TN93+G+I 
3 384 2201-2585 HKY+G 
4 4901 2587-7488 GTR+G+I 
5 891 7490-8381 GTR+G+I 
6 278 8383-8661 K2+G 
7 301 8664-8965 K2+G 
8 181 8971-9152 K2+G 
9 255 9154-9409 K2+G 
10 160 9400-9560 K2+G 
 
Table 4-5: Model test used to draw each tree for EC148 
Fragment Size of fragment (bp) HXB2 position Selected model 
 EC148 
NFLG 7709 790-8499 GTR+G 
1 381 790-1171 HKY+G 
2 1028 1172-2200 T93+G 
3 336 2201-2528 HKY+G 
4 1659 2529-4188 GTR+G+I 
5 550 4189-4731 T92+G 
6 2306 4732-7003 GTR+G+I 
7 1343 7005-8327 GTR+G 
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4.10. Inferring phylogenetic trees 
Multiple phylogenetic trees were inferred for each sample. A tree was inferred for the complete 
NFLG and multiple trees were inferred for each recombinant segment within the sample. All trees 
were constructed as Maximum Likelihood trees with bootstrap replicates of 1000. Maximum 
Likelihood trees were inferred as they provide more information and 1000 bootstrap replicates 
were used for accuracy. The reference sequence set used for the trees were retrieved from HIV 
LANL and is comprised of 39 group M sequences. For the complete NFLGs trees, an additional 
group N sequence was included in the reference sequence set, as an outlier. 
4.10.1. Sample WC416 
In total, eleven trees were inferred for sample WC416. The numbers 1-10 correspond to the 
position of each fragment relative to the HIV genome (Figure 4.11). Fragments 1, 5, 7 and 9 
identified as subtype A by jpHMM. In each tree the fragment sequences were most closely related 
to the subtype A reference sequences as they formed a distinct cluster together. The trees for 
fragments 1, 5 and 7 (Figure 4.12, Figure 4.16 and Figure 4.18, respectively) had bootstrap values 
greater than 70% and therefore the results can be accepted with confidence. However, for 
fragment 9 (Figure 4.20), the phylogenetic tree showed the sequence to be an outlier to the H and 
J reference sequences. The results displayed on this phylogenetic tree cannot be accepted with 
confidence due to the lack of bootstrap values over 70% and the short length (255bp) of the 
fragment sequence. 
Fragments 2, 4, 6 and 8 were assigned as subtype C by jpHMM. The phylogenetic tree for each 
fragment showed them to each cluster with the subtype C reference sequences. Fragment 2, 6 and 
8 (Figure 4.13, Figure 4.17, Figure 4.19, respectively) sequences formed distinct clusters with the 
subtype C reference sequences, however, fragment 4 (Figure 4.15) sequence was an outlier to the 
subtype C reference sequences. Fragment 2, 4 and 6 trees had bootstrap values over 70%. The 
tree for fragment 8 (Figure 19) had no bootstrap values over 70% and the sequences were short, 
therefore this result cannot be taken with confidence. 
Figure 4.11: Correspondence of fragment number to region on NFLG of WC416.  
The NFLG was divided into fragments based on the identification of different subtypes at different regions. 
The fragments were labelled 1-10 and a phylogenetic tree was inferred for each. 
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Fragment 3 was identified as subtype D by jpHMM. The phylogenetic tree showed the fragment 
sequence to be most closely related to subtype D, confirming the jpHMM results (Figure 4.14). The 
bootstrap values on the tree were over 70% and therefore the results could be accepted with 
confidence. The jpHMM results identified fragment 10 sequence as being located in the 5’LTR and 
was unable to assign a subtype to it. The phylogenetic tree inferred showed fragment 10 (Figure 
4.21) to be an outlier to subtype J reference sequences; however, this can’t be accepted with 
confidence due to the lack of bootstrap values greater than 70% on the tree and the short length 
(160bp) of the fragment sequence. 
The jpHMM results were confirmed by the phylogenetic tree results in 8 out of the 10 fragments 
(not in fragments 9 and 10). The sequential order of the different subtypes within the sample is 
identified as A, C, D, C, A, C, A, C, A. The phylogenetic tree inferred for the complete NFLG 
(Figure 4.22) is 8736bp and spans from the gag to the 3’LTR. The tree shows that the sample 
sequence is an outlier to the subtype C reference sequences. The tree nodes display bootstrap 
values of greater than 70% indicating that the results can be accepted with confidence. 
Therefore, the online subtyping programme and phylogenetic analyses identified sample WC416 
as a complex A, C, D recombinant form. 
 
 








Figure 4.12: Phylogenetic analysis of WC416 fragment 1.  
The sample sequence (circled in red) clusters with the A1 reference sequences. Bootstrap values >70% 
are shown at the nodes; scale of 0.02 used for branch lengths. The sequence locator result shows that 
the fragment is 369bp and located in the gag, HXB2 positions 826-1195. The jpHMM result identified the 
fragment as subtype A which is seen in red. 
Figure 4.13: Phylogenetic analysis of WC416 fragment 2 
The sample sequence is circled in red on the phylogenetic tree and clusters with the subtype C reference 
sequences. A horizontal scale of 0.01 was used for the branch lengths. The sequence locator result shows that 
the 999bp fragment is located in the gag, HXB2 1197-2196. jpHMM identified the fragment as subtype C which 
is seen in brown. 










Figure 4.14: Phylogenetic analysis of WC416 fragment 3 
The circled fragment sequence clusters most closely with the subtype D reference sequences. A 0.01 
horizontal scale was used for branch lengths.The sequence locator result shows that the fragment is 
384bp and is in the pol, HXB2 2201-2585. The jpHMM result identified the fragment as subtype D which 
is seen as pink. 
Figure 4.15: Phylogenetic analysis of WC416 fragment 4 
The circled fragment sequences clusters with the subtype C reference sequences. A horizontal branch 
length of 0.02 was used for branch length. The sequence locator result shows the fragment to be 4901bp 
and located from the pol to the env; HXB2 2587-7488. The jpHMM identified the fragment as subtype C, 
seen by the brown. 









Figure 4.17: Phylogenetic analysis of WC416 fragment 6 
The fragment sequence clusters with the subtype C reference sequences. A 0.02 horizontal scale was 
used for branch lengths. Sequence locator shows the fragment to be 278bp and located in the env; HXB2 
8383-8661. jpHMM assigned the sample as subtype C shown by the brown. 
Figure 4.16: Phylogenetic analysis of WC416 fragment 5 
The circled fragment sequence clusters with the subtype A1 reference sequences. A 0.02 horizontal scale 
was used for branch length. The sequence locator result shows the sample to be 891bp and is located in 
the env; HXB2 7490-8381. jpHMM assigned the fragment as subtype A as is seen by the red. 









Figure 4.19: Phylogenetic analysis of WC416 fragment 7 
The phylogenetic tree shows the fragment sequence clustering with the A1 reference sequences. A 0.05 
horizontal scale was used for branch length. The sequence locator result shows that the fragment is 
301bp and located in the env and nef. HXB2 8664-8965. jpHMM assigned this fragment as subtype A, 
indicated by the red. 
Figure 4.18: Phylogenetic analysis of WC416 fragment 8 
The phylogenetic tree shows the fragment sample clusters with the subtype C reference sequences. A 
horizontal scale of 0.05 was used for branch length. The fragment was identified to be 255bp and located in 










Figure 4.20: Phylogenetic analysis of WC416 fragment 9 
The phylogenetic tree shows the fragment to be an outlier to subtype H and J reference sequences 
however, the tree has no bootstrap values. A 0.01 scale was used for branch lengths. The sequence 
locator result shows the fragment to be 255bp and located in the nef/ 3’LTR; HXB2 9154-9409. jpHMM 
was not able to assign a subtype to this fragment. 
Figure 4.21: Phylogenetic analysis of WC416 fragment 10 
The phylogenetic tree shows the fragment clustering with subtype J reference sequences. No bootstrap 
values are indicated on the tree. A 0.02 scale was used for branch lengths. The sequence locator results 
show the sample to be 160bp and located in the 3’LTR; HXB2 9400-9560. jpHMM could not assign a subtype 
to the fragment. 




Figure 4.22: Phylogenetic tree of WC416 NFLG 
The phylogenetic tree inferred for WC416 complete NFLG showed the sample to be an outlier to the 
subtype C reference sequences. The sample sequence is denoted as 14.ZA.WC416 on the tree. 
Bootstrap values greater than 70% are shown at the nodes. A horizontal scale of 0.05 was used for the 
branch length. HIV-1 group M NFLG reference sequences, obtained from the Los Alamos database,  
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4.10.2. Sample EC148 
In total, 8 trees were inferred for this sample. The jpHMM results for the NFLG (Figure 4.8B) and 
just the env region of the NFLG (Figure 4.10) were combined (Figure 4.23) to give a more accurate 
representation of all subtypes identified in the sample. Each region of the NFLG that identified as a 
distinct subtype were separated into individual fragments. Seven fragments were identified in this 
sample. The fragments numbered 1-7 correspond to their positions relative to the HIV genome 
(Figure 4.23).  
 
 
Fragment 1 was identified as subtype A by jpHMM. The sequences clustered most closely to the 
subtype A1 reference sequences in the phylogenetic tree (Figure 4.24). The bootstrap value for 
this cluster was over 70% and therefore can be accepted with confidence, thereby confirming the 
jpHMM result. Fragment 2 was identified as subtype C by jpHMM. The phylogenetic tree for 
fragment 2 showed that the fragment sequence clustered with the subtype C reference sequences 
(Figure 4.25) with a bootstrap value of 100% at the node of the cluster. The phylogenetic result 
confirmed the jpHMM result for this fragment. The phylogenetic tree for fragment 3 illustrated that 
the fragment sequence clustered closely with the subtype D reference sequences (Figure 4.26). 
The bootstrap value at the node closest to the fragment sequence is greater than 70% therefore 
confirming the jpHMM result. Fragment 4 was identified by jpHMM as subtype C. Fragment 4 
sequences fell within the cluster of subtype C sequences on the phylogenetic tree, with bootstrap 
values greater than 70% (Figure 4.27). The jpHMM result and the phylogenetic tree result both 
identified this fragment as subtype C. Fragment 5 was identified as subtype K by jpHMM. The 
phylogenetic tree for this fragment showed that the fragment sequence was most closely related to 
the subtype C reference sequences (Figure 3.28). Although, the long branch length indicates that 
the query sequence is divergent from the subtype C reference sequences and there is no 
bootstrap value greater than 70% at that cluster. Fragment 6 was identified as subtype C by 
jpHMM. The phylogenetic tree for fragment 6 shows the fragment sequences clustering with the 
subtype C reference sequences, with greater than 70% bootstrap at the closest node (Figure 4.30). 
The jpHMM and phylogenetic tree results are consistent in assigning subtype C to this fragment. 
Figure 4.23 Correspondence of fragment number to position on HIV genome for EC148 
Fragments 1 and 2 are in the gag; 3, 4 and 5 are in the pol; 6 covers half of the vif, the vpr, vpu and half the 
env and 7 covers the remainder of the env. 
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Fragment 7 was identified by jpHMM as subtype A. The sequences for fragment 7 cluster with the 
subtype A1 reference sequences in the phylogenetic tree, with bootstrap values greater than 70% 
(Figure 4.29). Both the jpHMM and phylogenetic tree results identify fragment 7 as subtype A1. 
 
 
Figure 4.24: Phylogenetic analysis of EC148 fragment 1 
The phylogenetic tree shows the fragment sequence to be clustering with the A1 reference sequence. The 
fragment sequence is circled in red. A 0.05 horizontal branch scale was used. The sequence locator results 
show that the fragment is 381bp and located in the gag; HXB2 790-1171. jpHMM identified the fragment as 
subtype A which is indicated in red. 






Figure 4.25: Phylogenetic analysis of EC148 fragment 2 
The phylogenetic tree illustrates the fragment sequence, circled in red, clustering with the subtype C 
reference sequences. A 0.02 horizontal scale was used for branch length. The sequence locator results 
show that the 1028bp fragment is located in the gag; HXB2 1172-2200. jpHMM identified the fragment as 
subtype C. 
Figure 4.26: Phylogenetic analysis of EC148 fragment 3 
The phylogenetic tree shows the fragment sequence (circled in red) to cluster with the subtype D reference 
sequences. A 0.02 horizontal scale was used for branch length. The sequence locator image shows that the 
fragment is 336bp and located in the pol; HXB2 2201-2528. jpHMM assigned the fragment as subtype D as 
seen by the pink. 






Figure 4.27: Phylogenetic analysis of EC148 fragment 4 
The phylogenetic tree shows the fragment sequence, circled in red, to cluster with the subtype C reference 
sequences. A 0.02 horizontal scale was used for branch length. The sequence locator image shows that the 
fragment is 1659bp and is located in the pol; HXB2 2529-4188. jpHMM assigned the fragment as subtype C 
which is identified as brown. 




Figure 4.28: Phylogenetic analysis of EC148 fragment 5 
The phylogenetic tree shows that the fragment clusters with subtype C reference sequences. The fragment 
sequence is circled in red. A 0.02 horizontal scale was used for branch length. Sequence locator shows that 
the 542bp fragment is located in the pol; HXB2 4189-4731. jpHMM assigned the fragment as subtype K as 
seen by the purple. 





Figure 4.29: Phylogenetic analysis of EC148 fragment 6 
The phylogenetic tree shows the fragment to cluster with the subtype C reference sequences. The fragment 
is circled in red. A 0.02 horizontal scale is used for branch length. The sequence locator result shows the 
fragment to be 2306bp and located across the pol, vif, vpr, vpu and env; HXB2 4732-7003. jpHMM identified 
the fragment as subtype C which is identified by brown. 
Figure 4.30: Phylogenetic analysis of EC148 fragment 7 
The Phylogenetic tree shows that the fragment sequences cluster with the subtype A1 reference sequences. 
The fragment sequence is circles in red. A 0.05 horizontal scale was used for branch length. Sequence 
locator identified the 1343bp fragment to be located in the env; HXB2 7005-8327. jpHMM assigned the 
fragment as subtype A as is seen by the red. 
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The sample NFLG sequence begins in the gag and ends in the gp41 region of the env. The NFLG 
phylogenetic tree (Figure 4.31) shows the sample is an outlier to the subtype C reference 
sequences, with a 100% bootstrap value at the closest node. Bootstrap values greater than 70% 
are displayed at the nodes on the tree. The high bootstrap values on the tree indicate that the 
results can be accepted with confidence.  
Phylogenetic analysis confirmed the jpHMM results for all fragments expect for fragment 5. jpHMM 
identified this fragment as subtype K whereas the phylogenetic tree shows it to be most closely 
related to subtype C reference sequences. The phylogenetic analysis for each fragment and for the 
NFLG therefore confirms that the sample is a complex A, C, D recombinant. 
A phylogenetic tree was inferred with sample EC148 and WC416 NFLGs (Figure 4.32). The tree 
illustrates that both sample sequences cluster with each other in a separate cluster that is an 
outlier to the subtype C reference sequences in the tree. There is a 100% bootstrap value at the 
node of the cluster with the two sample sequences. There is also a 100% bootstrap value at the 
node joining this cluster to the subtype C reference sequences. Although sample EC148 and 
WC416 NFLG sequences cluster together, the longer branch length of EC148 indicate that they 
are different viruses.  




Figure 4.31: Phylogenetic tree of EC148 NFLG 
The phylogenetic tree shows the sample sequence to be an outlier to the subtype C reference 
sequences. The sample sequence is denoted as 12.ZA.EC.148. The numbers on the tree 
indicate bootstrap values above 70%. A 0.05 horizontal scale was used for branch length.  




Figure 4.32: Phylogenetic tree of sample EC148 and WC416 NFLGs 
Both sample sequences form an independent cluster that is an outlier to the subtype C 
reference sequences. Branch lengths greater than 70% are indicated on the tree. A branch 
scale of 0.05 was used. HIV-1 group M NFLG reference sequences, obtained from the Los 
Alamos database,  were used to infer the tree. 
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5.1. HIV-1 in South Africa 
5.1.1. Diversity in South Africa 
South Africa has the highest number of individuals infected with HIV worldwide. By the end of 2017 
this number was at 7.2 million individuals (UNAIDS, 2017). Based on sequences in the LANL 
database, subtype C accounts for 97.8% of the epidemic in South Africa, leaving 2.2% of the 
epidemic as non-subtype C (www.hivlanl.gov; Accessed 27/09/2018). Although 2.2% may appear 
as slightly insignificant in comparison to 97.8%, 2.2% of the 7.2 million infected individuals equates 
to 158 400 individuals. This figure of individuals infected by non-subtype C viruses in South Africa 
is larger than the total population of HIV infected individuals in countries such as Argentina and 
Mali, where the number of people living with HIV are 120 000 and 130 000, respectively (UNAIDS, 
2017). However, these numbers only represent sequences from which the sampling country is 
known and is not an accurate representation of the true statistics. This study focused on 
characterisation of non-subtype C viruses circulating in South Africa. 
The co-circulation of subtype C and non-subtype C viruses in South Africa indicate the complexity 
of the epidemic. The characterisation of the two non-subtype C viruses in this study will contribute 
to understanding the epidemic in South Africa. The characteristics of different HIV-1 strains and 
their interaction with the human host may play a role in HIV transmission and disease progression. 
For example, strains that use the CCR5 chemokine receptor are transmitted more frequently than 
those that use the CXCR4 receptor (Taylor et al., 2008). HIV-1 diversity also has implications in 
molecular diagnostic assays, ART and vaccine development (Peeters, 2001). A standard 
diagnostic assay, ART regime or vaccine would not be suitable for an epidemic of high diversity 
(Lau and Wong, 2013).  
5.1.2. Implications of HIV-1 diversity 
Our cohort of possible C, D recombinant viruses in South Africa (Table 4.1) indicate that the 
epidemic is diverse. With over 6000 non-subtype C viral sequences obtained by the NHLS in a 
period of 7 years (2008-2015), it is evident that large numbers of non-subtype C viruses are 
circulating in the country (unpublished data; Prof S. Engelbrecht – personal communication). HIV 
diversity can have an impact on diagnosis and the ability to accurately determine viral load 
measurements (Bourlet et al., 2011; Church et al., 2011). Viral diversity may also play a role in the 
emergence of drug resistance by affecting the response to ART (Tatem et al., 2012). Studies have 
shown that subtypes may differ in their rate of progression to disease as well as in the rate of 
transmission of the virus (Kiwanuka et al., 2008, 2009). An example of this is seen with the K65R 
mutation that confers drug resistance mutation in HIV-1 subtype C viruses (Doualla-Bell et al., 
2006). A study by Hemelaar, 2013 identified numerous aspects of HIV infection that are affected by 
HIV genetic variability. These aspects include vaccine development, transmission routes, disease 
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progression, drug resistance, response to ART, viral load measurement, diagnosis, pathogenesis 
and immune response and escape (Figure 5.1) (Hemelaar, 2013). Monitoring the diversity within 
the country is therefore crucial as it assists in important aspects of HIV infection. 
 
5.1.3. Characterisation of HIV-1 non-subtype C viruses in South Africa 
To date, to the best of our knowledge and based on available sequences in the LANL database, 22 
non-subtype C NFLG virus sequences have been characterised in South Africa, 14 are pure 
subtypes and 8 are recombinant forms. The pure subtypes are comprised of 3 subtype A1 viruses 
(Rousseau et al., 2006; Wilkinson and Engelbrecht, 2009; Wilkinson et al., 2015b); 5 subtype B 
viruses (Rousseau et al., 2006; Wilkinson and Engelbrecht, 2009; Wilkinson et al., 2015b); 5 
subtype D (Loxton et al., 2005; Jacobs et al., 2007) and 1 subtype G virus (Wilkinson et al., 
2015b). The recombinant viruses comprise of 5 A, C recombinants (Papathanasopoulos et al., 
2002; Rousseau et al., 2006; Iweriebor et al., 2011; Wilkinson et al., 2015b); 2 A, D recombinants 
(Wilkinson and Engelbrecht, 2009; Wilkinson et al., 2015b) and 1 complex recombinant 
(Papathanasopoulos et al., 2002). 
Characterisation of the two samples from this study will increase the number of non subtype C 
NFLGs in South Africa from 22 to 24. The two study samples were selected based on the sample 
availability and sample volume. Numerous samples from the C, D cohort were used to attempt to 
amplify the NFLG, however they did not yield positive results. only two of the samples, EC148 and 
WC416, were available, of sufficient volume and yielded positive results from the NFLG PCR 
amplification. Therefore only these two samples could be used for further characterisation. The two 
sequences from the viruses characterised in this study each identify as a complex A, C, D URF. 
Although, subtypes A, C and D are identified in both samples, the breakpoints between the 
subtypes differ in each. In WC416, BLAST results showed the subtype A segment to be most 
similar to an A, C recombinant from Malawi in 2009 and the subtype D segment showed highest 
Figure 5.1: Aspects of HIV infection affected by HIV diversity (adapted from Hemelaar, 2013) 
Diagram depicting the different aspects found to be associated with HIV infection and HIV diversity. HIV 
diversity plays a role in multiple different aspects of HIV research. 
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similarity to an A, C, D ,G complex recombinant from Tanzania in 2009. The subtype A segment of 
EC148 is most similar to an A, C recombinant from Tanzania in 1997 and the subtype D segment 
was most similar to a subtype D virus from Uganda in 2005. These results reveal that EC148 and 
WC416 viruses are not the same.  
Subtype A is dominant in Central African Republic and is responsible for 73.4% of the epidemic. 
Subtype A is also highly prevalent in the former Union of Soviet Socialist Republics (USSR) region, 
especially in Kazakstan and Kyrgyzstan, where it dominates the epidemics by more than 90%. 
Subtype D is most prevalent in Central African countries such as Uganda, Sudan and Chad where 
subtype D dominates their epidemics by 59.1%, 56.4% and 41.7%, respectively. Subtype C is 
highly prevalent in South Africa, accounting for 97.8% of South African HIV-1 sequences in the 
LANL database. These statistics are based only on sequences available in the HIV LANL database 
(https://www.hiv.lanl.gov; Accessed 20/09/18). Subtype D, along with subtype B, was also once a 
predominant subtype in South Africa during the first epidemic in the 1980s. With subtype A and D 
being predominant in Central African counties, it is possible that these subtypes come to South 
Africa via refugees that are driven out of their native countries due to political unrest (Wilkinson and 
Engelbrecht, 2009). World travel also influences HIV diversity and could be responsible for the 
transfer of subtypes into South Africa from other parts of the world (Perrin, 2003). Given that 
subtype A, C and D have been identified as pure subtypes and as recombinant forms (A, C and A, 
D) circulating in South Africa, the formation of an A, C, D complex recombinant is indeed plausible.  
5.2. Importance of HIV-1 recombinant forms 
5.2.1. Significance 
No less than 20% of global HIV-1 isolates sequenced are recombinant forms (Hemelaar et al., 
2006). By the end of October 2018, 97 recombinant forms have been identified in the 
LANLdatabase (https://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html; Accessed 
27/10/2018). The most prevalent recombinant is CRF01_AE, which accounts for 5.9% of all HIV-1 
sequences available in the LANL database. CRF01_AE is prevalent in South East Asia and is the 
predominant subtype in countries including Thailand, Cambodia and Vietnam, having displaced the 
previous existing HIV-1 subtype. Another common recombinant is CRF02_AG (Haynes et al., 
1995, Hemelaar, 2012), which is responsible for over 9 million infections globally ( Haynes et al., 
1995). This particular recombinant virus is the predominant strain in West and West Central Africa, 
particularly in Libya where 100% (n =148) of the HIV-1 sequences in LANL from that country are 
CRF02_AG. The emergence of recombinant forms has been on the increase since the discovery of 
the first CRF in 1992 (Figure 5.2). HIV-1 recombinant viruses are emerging at a high frequency as 
a results of co/super infection of individuals and due to the co-circulation of multiple subtypes in 
nearly all geographical regions. Africa, Asia and South America have been identified as the three 
geographical regions with the highest prevalence of CRFs, globally (Lau and Wong, 2013). 




5.2.2. Implications of HIV-1 recombination 
Both samples used in this study identified as complex HIV-1 recombinant forms. Recombination of 
different HIV-1 subtypes is believed to have an impact on viral diversity and fitness, drug 
resistance, disease progression and escape from the immune system. Recombination is often 
observed in the evolution of HIV in infected patients. Such recombination events are able to confer 
new combinations of phenotypic traits that are frequently advantageous for the virus. These 
advantageous traits have the potential to contribute to the increase in fitness of the virus (Brown et 
al., 2011). Recombination of HIV-1 within an infected patient has shown to contribute to the viral 
diversity of viral quasispecies by generating novel genotypes in HIV-1 genes (Charpentier et al., 
2006). Genetic recombination of divergent HIV-1 strains in a co-infected individual can lead to the 
emergence of drug resistant mutant viruses. When a virus that confers resistance to drug A 
combines with a virus that confers resistance to drug B, a mutant virus is generated that confers 
resistance to both drug A and B (Moutouh et al., 1996). Recombination also plays a role in the 
alteration of HIV-1 to changing selective pressure such as from ART. This can be done by 
producing viruses with new combinations of resistance mutations, compared to the parent viruses 
or by increasing diversity in the genomic regions that are not exposed to such selective pressure. 
For example while diversity decreases in the pol due to selective pressure, there is an increase in 
diversity in the gag and env (Nora et al., 2007). This highlights the importance of complete 
genome/NFLG characterisation to detect the true diversity in a sample sequence. Recombination 
is also associated with immunological escape. In an instance where superinfection occurs in an 
Figure 5.2: Increased emergence of CRFs (Lau and Wong, 2013) 
The y axis of the graph represents the number of reported CRFs and the x axis represents the years from 
1993-2012. The red line represents the global number, green represents Africa, blue represents Asia, pink 
represents South America and purple represents other regions. 
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infected individual, the superinfecting strain is able to evade the existing immune control possibly 
by recombination with the initial strain in critical regions under immune selection pressure (Streeck 
et al., 2008). Recombination between multiple viruses show a greater likelihood of escaping 
primary CD8+ T-cells as compared to single virus infections (Ritchie et al., 2014). Recombination 
of divergent HIV-1 strains is sometimes associated with increased viral fitness leading to the ability 
to evade the human immune cells and therefore possibly accelerate the progression to AIDS (Liu 
et al., 2002). A study by Kiwanuka et al., 2008 shows that infection with an A, D recombinant lead 
to a more rapid progression to AIDS than infection with a pure subtype A virus. CRF19_cpx 
(Subtypes D, A and G) in the Cuban population is also associated with faster progression to AIDS 
and high pathogenicity (Kouri et al., 2015). 
5.3. Near full-length genome characterisation 
Characterisation of partial genes or small fragments of the HIV genome to subtype an isolate has 
been widely used in the past (Jacobs et al., 2009; Grossmann et al, 2015; Neogi et al., 2012). 
Such characterisation may only give an indication of the possible subtype of the isolate. Partial 
genome sequencing is especially not useful in identifying recombinants as a recombinant segment 
can be at any region within the genome.  
The samples in the non-subtype C cohort, from which the study samples were obtained, were all 
initially only sequenced in the partial pol region of the genome (~1.4kb) and identified as possible 
C, D recombinants. using only the pol sequences of a virus to identify recombination will lead to an 
inaccurate representation of the true recombinant viruses circulating in the country. NFLG 
sequencing done in this study identified the samples instead as complex A, C, D recombinants, 
highlighting the importance of NFLG characterisation for recombinant identification. NFLG 
characterisation allows one to make a more accurate assumption of the subtype and 
recombination pattern of an isolate (Wilkinson and Engelbrecht, 2009). It allows for the detection of 
all possible subtypes within a sample even if it is only in a small region. NFLG must be used in 
order to identify possible recombinants circulating in the country. 
5.4. Study strengths and limitations 
In this study we were able to characterise two complex A, C, D unique recombinants. The PCR 
protocols were optimised to work for DNA and viral RNA samples. We were able to obtain NFLG 
sequences of over 7000bp for each sample using in house primers as well as designed primers for 
regions that proved difficult to sequence. All protocols displayed in this study can be repeated and 
can therefore contribute to an increase in the number of NFLG sequences in South Africa. 
A limitation to this study was the discrepancies between the online subtyping programs. For 
sample EC148, jpHMM identified a substantial region of the genome as subtype K whereas RIP 
and REGA assigned the same region as subtype C. An additional limitation was conferring 
Stellenbosch University  https://scholar.sun.ac.za
 
73 
phylogenetic trees for small regions that identified as distinct subtypes. The phylogenetic trees 
results for these regions didn’t have bootstrap values >70% as they were less than 500bp in 
length.   




Two unique HIV-1 NFLG complex A, C, D recombinants have been identified in this study. It is 
important to monitor the diversity of HIV-1 in the country as the emergence of new recombinants 
indicates that the epidemic is complex and constantly evolving. NFLG characterisation of HIV-1 
allows for a more accurate representation of recombinant forms and increases our knowledge on 
circulating viruses in the country.   
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AGGCCTTTTCTTCTACTACTTTTA 1279-1256 Dr Hackett 
JR 
Reverse 
P24-7 CCCTGRCATGCTGTCATCA 1832-1850 Swanson et 
al.,2003 
Forward 
P24_2 AGACYTTAAGCATGGGT 1237-1256 Dr Hackett 
JR 
Forward 
RTC CATTTGTCAGGATGGAGTTCATA 3265-3243 Rosseau et 
al., 2006 
Reverse 
RTC CATTTGTCAGGATGGAGTTCATA 3265-3243 Rosseau et 
al., 2006 
Reverse 





3742-3779 Designed Forward 
POLI05 CACACAAAGGRATTGGAGGAAATG 4177-4200 Swanson et 
al.,2003 
Forward 
6231R CTCTCATTGCCACTGTCTTCTGCTC 6231-6207 Grossman 
et al.,2015 
Reverse 
5550F AGAGAAGATGGAACAAGCCCCAG 5550-5574 Grossman 
et al.,2015 
Forward 














AATCGCAAAACCAGCTGGAGCAC 6899-6875 Dr Hackett 
JR 
Reverse 
FGF46 GCATTCCCTACAATCCCCAAAG 4648-4669 Gao et 
al.,1996 
Forward 





ENV-1 CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA 5940-5982 In-house Forward 
LP7725R GTCCAATGCCAATAAGTCTTGTTC 8216-8193 Dr Hackett 
JR 
Reverse 
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Table 0-2: Sequencing primers used to sequence sample WC416 
Sample 416 















1237-1256 Dr Hackett JR Forward 
GAGa AGAGAACCAAGGG
GAAGTGA 
1654 - 1673 Kemp et al, 1989 Forward 
RTC CATTTGTCAGGATG
GAGTTCATA 




















5276-5301 Dr Hackett JR Forward 
5550F AGARGAYAGATGG
AACAAGCCCCAG 


























3742-3779 Designed Forward 
p24-6 TGTGWAGCTTGYT
CRGCTC 




















7789-7816 Dr Hackett JR Forward 
NEF416F GGGACGCAGCAGT
CTCCAGGGAC 
9287-9307 Designed Forward 
NEF416R CAAGGCTACTTCCC
TGACTGGCAG 
9171-9148 Designed Reverse 















6899-6875 Dr Hackett JR Reverse 
ED5 ATGGGATCAAAGC
CTAAAG CCATGTG 
6134 -6159 Delwart et al.,1993 Forward 
LP-7725R GTCCAATGCCAATA
AGTCTTGTTC 
8216-8193 Dr Hackett JR Reverse 
FGF46 GCATTCCCTACAAT
CCCCAAAG 
4648-4669 Gao et al.,1996 Forward 
FGR95 GGTCTAACCAGAG
AGACCCAGTACAG 
9557-9532 Gao et al., 1996 Reverse 
 




Figure 0.1: Study ethics approval letter for 2018 
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